<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antidepressants for the treatment of depression in people with cancer - Vita, G - 2023 | Cochrane Library</title> <meta content="Antidepressants for the treatment of depression in people with cancer - Vita, G - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011006.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antidepressants for the treatment of depression in people with cancer - Vita, G - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011006.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011006.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antidepressants for the treatment of depression in people with cancer" name="citation_title"/> <meta content="Giovanni Vita" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="giovanni.vita@univr.it" name="citation_author_email"/> <meta content="Beatrice Compri" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Faith Matcham" name="citation_author"/> <meta content="University of Sussex" name="citation_author_institution"/> <meta content="Corrado Barbui" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Giovanni Ostuzzi" name="citation_author"/> <meta content="University of Verona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011006.pub4" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/03/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011006.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011006.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011006.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents [therapeutic use]; Antidepressive Agents, Tricyclic [therapeutic use]; Depression [drug therapy, etiology]; *Depressive Disorder, Major [drug therapy]; Mirtazapine [therapeutic use]; *Neoplasms [drug therapy]; Selective Serotonin Reuptake Inhibitors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011006.pub4&amp;doi=10.1002/14651858.CD011006.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Nio3SV1W";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011006\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011006\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ko","pt","th","ms","ja","hr","fa","id","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011006.pub4",title:"Antidepressants for the treatment of depression in people with cancer",firstPublishedDate:"Mar 31, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011006.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011006.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011006.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011006.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011006.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011006.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati telaah sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011006.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011006.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011006.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011006.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5533 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011006.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/appendices#CD011006-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/supinfo/CD011006StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/supinfo/CD011006StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antidepressants for the treatment of depression in people with cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#CD011006-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni Vita</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#CD011006-cr-0005">Beatrice Compri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#CD011006-cr-0006">Faith Matcham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#CD011006-cr-0007">Corrado Barbui</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information#CD011006-cr-0008">Giovanni Ostuzzi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information/en#CD011006-sec-0132">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 March 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011006.pub4">https://doi.org/10.1002/14651858.CD011006.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011006-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011006-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011006-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011006-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011006-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011006-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD011006-abs-0008">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011006-abs-0001" lang="en"> <section id="CD011006-sec-0001"> <h3 class="title" id="CD011006-sec-0001">Background</h3> <p>Major depression and other depressive conditions are common in people with cancer. These conditions are not easily detectable in clinical practice, due to the overlap between medical and psychiatric symptoms, as described by diagnostic manuals such as the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) and <i>International Classification of Diseases</i> (ICD). Moreover, it is particularly challenging to distinguish between pathological and normal reactions to such a severe illness. Depressive symptoms, even in subthreshold manifestations, have a negative impact in terms of quality of life, compliance with anticancer treatment, suicide risk and possibly the mortality rate for the cancer itself. Randomised controlled trials (RCTs) on the efficacy, tolerability and acceptability of antidepressants in this population are few and often report conflicting results. </p> </section> <section id="CD011006-sec-0002"> <h3 class="title" id="CD011006-sec-0002">Objectives</h3> <p>To evaluate the efficacy, tolerability and acceptability of antidepressants for treating depressive symptoms in adults (aged 18 years or older) with cancer (any site and stage). </p> </section> <section id="CD011006-sec-0003"> <h3 class="title" id="CD011006-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was November 2022. </p> </section> <section id="CD011006-sec-0004"> <h3 class="title" id="CD011006-sec-0004">Selection criteria</h3> <p>We included RCTs comparing antidepressants versus placebo, or antidepressants versus other antidepressants, in adults (aged 18 years or above) with any primary diagnosis of cancer and depression (including major depressive disorder, adjustment disorder, dysthymic disorder or depressive symptoms in the absence of a formal diagnosis). </p> </section> <section id="CD011006-sec-0005"> <h3 class="title" id="CD011006-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcome was 1. efficacy as a continuous outcome. Our secondary outcomes were 2. efficacy as a dichotomous outcome, 3. Social adjustment, 4. health‐related quality of life and 5. dropouts. We used GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD011006-sec-0006"> <h3 class="title" id="CD011006-sec-0006">Main results</h3> <p>We identified 14 studies (1364 participants), 10 of which contributed to the meta‐analysis for the primary outcome. Six of these compared antidepressants and placebo, three compared two antidepressants, and one three‐armed study compared two antidepressants and placebo. In this update, we included four additional studies, three of which contributed data for the primary outcome. </p> <p>For acute‐phase treatment response (six to 12 weeks), antidepressants may reduce depressive symptoms when compared with placebo, even though the evidence is very uncertain. This was true when depressive symptoms were measured as a continuous outcome (standardised mean difference (SMD) −0.52, 95% confidence interval (CI) −0.92 to −0.12; 7 studies, 511 participants; very low‐certainty evidence) and when measured as a proportion of people who had depression at the end of the study (risk ratio (RR) 0.74, 95% CI 0.57 to 0.96; 5 studies, 662 participants; very low‐certainty evidence). No studies reported data on follow‐up response (more than 12 weeks). In head‐to‐head comparisons, we retrieved data for selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs) and for mirtazapine versus TCAs. There was no difference between the various classes of antidepressants (continuous outcome: SSRI versus TCA: SMD −0.08, 95% CI −0.34 to 0.18; 3 studies, 237 participants; very low‐certainty evidence; mirtazapine versus TCA: SMD −4.80, 95% CI −9.70 to 0.10; 1 study, 25 participants). </p> <p>There was a potential beneficial effect of antidepressants versus placebo for the secondary efficacy outcomes (continuous outcome, response at one to four weeks; very low‐certainty evidence). There were no differences for these outcomes when comparing two different classes of antidepressants, even though the evidence was very uncertain. </p> <p>In terms of dropouts due to any cause, we found no difference between antidepressants compared with placebo (RR 0.85, 95% CI 0.52 to 1.38; 9 studies, 889 participants; very low‐certainty evidence), and between SSRIs and TCAs (RR 0.83, 95% CI 0.53 to 1.22; 3 studies, 237 participants). </p> <p>We downgraded the certainty of the evidence because of the heterogeneous quality of the studies, imprecision arising from small sample sizes and wide CIs, and inconsistency due to statistical or clinical heterogeneity. </p> </section> <section id="CD011006-sec-0007"> <h3 class="title" id="CD011006-sec-0007">Authors' conclusions</h3> <p>Despite the impact of depression on people with cancer, the available studies were few and of low quality. This review found a potential beneficial effect of antidepressants against placebo in depressed participants with cancer. However, the certainty of evidence is very low and, on the basis of these results, it is difficult to draw clear implications for practice. The use of antidepressants in people with cancer should be considered on an individual basis and, considering the lack of head‐to‐head data, the choice of which drug to prescribe may be based on the data on antidepressant efficacy in the general population of people with major depression, also taking into account that data on people with other serious medical conditions suggest a positive safety profile for the SSRIs. Furthermore, this update shows that the usage of the newly US Food and Drug Administration‐approved antidepressant esketamine in its intravenous formulation might represent a potential treatment for this specific population of people, since it can be used both as an anaesthetic and an antidepressant. However, data are too inconclusive and further studies are needed. We conclude that to better inform clinical practice, there is an urgent need for large, simple, randomised, pragmatic trials comparing commonly used antidepressants versus placebo in people with cancer who have depressive symptoms, with or without a formal diagnosis of a depressive disorder. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011006-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011006-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011006-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011006-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011006-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011006-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011006-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD011006-abs-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011006-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011006-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011006-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011006-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD011006-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011006-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011006-abs-0002" lang="en"> <h3>Antidepressants for the treatment of depression in people with cancer</h3> <p><b>Key messages</b> </p> <p>This review found a potential beneficial effect of antidepressants against placebo (a pretend treatment) in depressed people with cancer. However, evidence is uncertain and it is difficult to draw clear conclusions. The use of antidepressants in people with cancer should be considered on an individual basis. </p> <p><b>What is the issue?</b> </p> <p>Depression is frequent amongst people with cancer. Often depressive symptoms are a normal reaction or a direct effect of such a severe and life‐threatening illness. Therefore, it is difficult to establish when depressive symptoms become a proper disorder and need to be treated with medicines. Current scientific literature reveals that depressive symptoms, even when mild, can have an impact on the course of cancer, reducing people's overall quality of life and affecting their compliance with anticancer treatment, as well as possibly increasing the likelihood of death. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to assess the effectiveness and acceptability of antidepressants for treating depressive symptoms in people with cancer at any site of the body and severity. </p> <p><b>What did we do?</b> </p> <p>We searched medical databases for well‐designed clinical studies comparing antidepressants versus placebo, or antidepressants versus other antidepressants in adults with a diagnosis of cancer and depression. </p> <p><b>What did we find?</b> </p> <p>We reviewed 14 studies assessing the effectiveness of antidepressants in 1364 participants. We found that antidepressants may reduce depressive symptoms after six to 12 weeks of treatment in people with cancer. There was not enough evidence to determine how well antidepressants were tolerated in comparison with placebo. The results did not show whether any particular antidepressant was better than any other antidepressant in terms of beneficial or harmful effects. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our certainty in the evidence was very low because of a lack of information about how the studies were designed, low numbers of people in the analysis of results, and differences between the characteristics of the studies and their results. </p> <p><b>What are the conclusions?</b> </p> <p>Despite the impact of depression on people with cancer, the available studies were very few and of low quality. We observed a small potential beneficial effect of antidepressants in treating depressive symptoms in people with cancer. However, this finding was supported by very low‐quality evidence. To better inform doctors and patients, we need larger studies that randomly assign people to different treatments. Currently, it is difficult to draw reliable conclusions about the effects of antidepressants on depression in people with cancer. Our review seems to indicate that people with cancer should be treated in a similar way to the general population for the management of depressive symptoms. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is current to November 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011006-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011006-sec-0107"></div> <h3 class="title" id="CD011006-sec-0108">Implications for practice</h3> <section id="CD011006-sec-0108"> <p>There is a very low number of randomised controlled trials assessing the efficacy of antidepressants in people with cancer, despite the relevance of this issue. Moreover, evidence for the effects we have found in terms of the efficacy and acceptability of antidepressants in people with cancer is of very low certainty. Data from the review revealed a small beneficial overall effect of antidepressants as a class over placebo, even though the certainty of evidence is very low (<a href="#CD011006-fig-0002">Figure 2</a>). </p> <p>This review found a small beneficial effect of selective serotonin reuptake inhibitors (SSRIs) compared to placebo in people with cancer and depression. Although the certainty of evidence of these results is very low, SSRIs are the first‐line treatment for the management of clinically relevant depression and their efficacy in the general population has been showed by various clinical studies (<a href="./references#CD011006-bbs2-0129" title="CiprianiA , FurukawaTA , SalantiG , GeddesJR , HigginsJP , ChurchillR , et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet2009;373:746-58. [DOI: 10.1016/S0140- 6736(09)60046-5]">Cipriani 2009</a>). According to the evidence at our disposal, SSRIs seem to be effective also in individuals with cancer, and they should probably only be prescribed as first‐line treatment when depressive symptoms become clinically relevant. </p> <p>Esketamine and mianserin (included in the 'other antidepressants class') have a small beneficial effect against placebo. Mianserin is considered to have a similar profile to mirtazapine, the efficacy of which has been largely demonstrated, but with a possible unfavourable tolerability profile with respect to SSRIs (<a href="./references#CD011006-bbs2-0129" title="CiprianiA , FurukawaTA , SalantiG , GeddesJR , HigginsJP , ChurchillR , et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet2009;373:746-58. [DOI: 10.1016/S0140- 6736(09)60046-5]">Cipriani 2009</a>). In contrast, esketamine has been approved as an antidepressant (<a href="./references#CD011006-bbs2-0160" title="KimJ , FarchioneT , PotterA , ChenQ , TempleR . Esketamine for treatment-resistant depression – First FDA-approved antidepressant in a new class. New England Journal of Medicine2019;381:1-4. [DOI: 10.1056/NEJMp1903305]">Kim 2019</a>). Since the intravenous formulation of esketamine can be used also as an anaesthetic, it can prove useful in the treatment of those people with cancer who have to undergo a surgery. The efficacy, tolerability and acceptability of these drugs in severely medically ill people is yet to be assessed. Thus, the clinical meaning of these results is uncertain and no clear implications for clinical practice can be drawn. Similarly, no differences between the various classes of antidepressants (in head‐to‐head comparisons) emerged (<a href="#CD011006-fig-0003">Figure 3</a>). </p> <p>Finding an appropriate treatment for depressive symptoms in people with cancer is a relevant goal in routine clinical practice, as shown by the ongoing discussion in the scientific literature. There is a growing awareness of the need for a multidimensional approach, encompassing biological, social and psychological issues, as highlighted by previous reviews (<a href="./references#CD011006-bbs2-0104" title="AkechiT , OkuyamaT , OnishiJ , MoritaT , FurukawaTA . Psychotherapy for depression among incurable cancer patients. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD005537. [DOI: 10.1002/14651858.CD005537.pub2]">Akechi 2008</a>; <a href="./references#CD011006-bbs2-0139" title="GalwayK , BlackA , CantwellM , CardwellCR , MillsM , DonnellyM . Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD007064. [DOI: 10.1002/14651858.CD007064.pub2]">Galway 2012</a>; <a href="./references#CD011006-bbs2-0210" title="SmithHR . Depression in cancer patients: pathogenesis, implications and treatment (review). Oncology Letters2015;9(4):1509-14. [DOI: 10.3892/ol.2015.2944]">Smith 2015</a>). A proper evaluation of subthreshold depressive symptoms seems essential, also considering their potentially relevant impact on the prognosis of cancer, although it is not easy to discern when it is worthwhile to introduce an antidepressant. Very few and unspecific indications could be derived from the available guidelines (<a href="./references#CD011006-bbs2-0143" title="GrassiL , NanniMG , RodinG , LiM , CarusoR . The use of antidepressants in oncology: a review and practical tips for oncologists. Annals of Oncology2018;29(1):101-11. [DOI: 10.1093/annonc/mdx526]">Grassi 2018</a>; <a href="./references#CD011006-bbs2-0175" title="National Institute for Health and Clinical Excellence (NICE). Depression in adults with a chronic physical health problem. Treatment and management [CG91]. www.nice.org.uk/guidance/cg91 (accessed prior to 30 March 2023).">NICE 2009</a>; <a href="./references#CD011006-bbs2-0192" title="RaynerL , PriceA , HotopfM , HigginsonIJ . The development of evidence-based European guidelines on the management of depression in palliative cancer care. European Journal of Cancer2011;47:702-12.">Rayner 2011b</a>). In general, based on the results of the current review, the possible role of antidepressants is still controversial and should be assessed each time by the clinician on an individual basis. The choice of which antidepressant to prescribe can hardly be made on the basis of this review; rather, it may be based on the data on antidepressant efficacy in the general population of people with major depression. Additionally, the data on antidepressant efficacy in medically ill people — which suggest a positive safety profile of SSRIs (<a href="./references#CD011006-bbs2-0190" title="RaynerL , PriceA , EvansA , ValsrajK , HigginsonIJ , HotopfM . Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007503. [DOI: 10.1002/14651858.CD007503.pub2]">Rayner 2010</a>; <a href="./references#CD011006-bbs2-0191" title="RaynerL , PriceA , EvansA , ValsrajK , HotopfM , HigginsonIJ . Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliative Medicine2011;25(1):36-51.">Rayner 2011a</a>) — may also be considered. </p> </section> <h3 class="title" id="CD011006-sec-0109">Implications for research</h3> <section id="CD011006-sec-0109"> <p>The results described in this systematic review come from evidence of very low certainty according to GRADE methodology. Moreover, in many cases studies were financially supported by pharmaceutical industries. Consequently, there is a high risk that these studies do not provide sufficient and adequate information for clinicians in real‐world settings. The present review highlights the strong need for further studies, which should be conducted to high methodological standards and with the primary intent of providing clinicians with useful practical data on the effectiveness of antidepressant drugs, firstly over placebo and subsequently in head‐to‐head comparisons. Alongside rating scales, pragmatic outcome measures, such as quality of life and social functioning, should also be considered. </p> <p>Despite the high prevalence of depression in people with cancer and its substantial impact, the number of RCTs assessing the efficacy of antidepressants in oncology is still very low. We recognise that these studies are extremely difficult to conduct, as depression is not always considered a major concern by doctors and by people with cancer, who are sometimes reluctant to admit its existence. Moreover, promoting this type of study may be not considered as a priority for anticancer research funding agencies. </p> <p>Further basic research on the pathogenetic pathways of depression in medically ill people is needed. This could be helpful for identifying possible therapeutic targets, and would also allow the assessment of new, possibly effective drugs with comparative studies designs. In recent years, we witnessed a growing interest in detecting possible specific mechanisms involved in pathogenesis of depressive experiences in different types of cancer (<a href="./references#CD011006-bbs2-0116" title="BotwinickIC , PursellL , YuG , CooperT , MannJJ , ChabotJA . A biological basis for depression in pancreatic cancer. HPB – Official Journal of the International Hepato Pancreato Biliary Association2014;16(8):740-3. [DOI: 10.1111/hpb.12201]">Bowinik 2014</a>; <a href="./references#CD011006-bbs2-0212" title="SoteloJL , MusselmanD , NemeroffC . The biology of depression in cancer and the relationship between depression and cancer progression. International Review of Psychiatry2014;26(1):16-30.">Sotelo 2014</a>). </p> <p>Generally SSRIs are considered to have a good therapeutic index amongst antidepressants. However, some other antidepressants could be theoretically helpful in this particular population, being possibly effective not only for depression, but also for medical symptoms. For example, some non‐randomised controlled studies are available on the effect of mirtazapine for insomnia and hyporexia, or duloxetine for pain perception, hot flushes, etc. In actuality there are no RCTs in people with cancer available with these compounds. </p> <p>There is a growing interest in discussing the potential benefit of intravenous esketamine in reducing depressive symptoms. Two studies included in this update studied the efficacy of intravenous esketamine in participants with cancer who undergo a surgical operation, showing a potential positive effect over placebo, especially in the short‐term follow‐up assessments (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). </p> <p>Other studies showed promising results concerning the use of psychedelics and psychostimulants (psylocibin, methylphenidate) to treat depression in people with cancer (<a href="./references#CD011006-bbs2-0031" title="GriffithsRR , JohnsonMW , CarducciMA , UmbrichtA , RichardsWA , RichardsBD , et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. Journal of Psychopharmacology2016;30(12):1181-97. [DOI: 10.1177/0269881116675513]">Griffiths 2016</a>; <a href="./references#CD011006-bbs2-0058" title="NCT01219673. Symptom burden in head and neck cancer. clinicaltrials.gov/ct2/show/NCT01219673 (first received 13 October 2010). ">NCT01219673</a>). However, these studies were not included in the meta‐analysis since the use of these drugs is not approved by the US Food and Drug Administration to treat depression. </p> <p>In line with the conclusions from the previous version of this review, in order to increase the evidence on the compelling issue of depressive symptoms in people with cancer, there is a need for large, simple, pragmatic studies comparing commonly used antidepressants (SSRIs, serotonin‐noradrenaline reuptake inhibitors, mirtazapine) versus placebo in individuals with cancer and depressive symptoms, with or without a formal diagnosis of a depressive disorder. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011006-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011006-sec-0008"></div> <div class="table" id="CD011006-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antidepressants compared to placebo for people with cancer and depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Antidepressants compared to placebo for people with cancer and depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> adults with cancer and depression<br/><b>Settings:</b> inpatient and outpatient<br/><b>Intervention:</b> antidepressants<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Antidepressants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a continuous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy as a continuous outcome (SMD) in the intervention groups was<br/><b>0.52 standard deviations lower</b><br/>(0.92 lower to 0.12 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511 <br/>(7 studies, 8 comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a dichotomous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>427 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b><br/>(243 to 410) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/>(0.57 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>662 <br/>(7 studies, 8 comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts due to any cause (acceptability)</b><br/>Follow‐up: 4–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b><br/>(105 to 328) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/>(0.52 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>479<br/>(9 studies, 10 comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level as the general quality of the studies included in the review was poor, with 50% of the studies at high risk of bias in the ROB 2 assessment. Most studies had a very high dropout rate (bias due to missing outcome) and very few studies described the randomisation process in detail.<br/><sup>b</sup> Downgraded two levels due to serious heterogeneity (I² = 74%). An I² statistic between 50% and 75% suggests a serious risk of inconsistency (unexplained heterogeneity), which may arise from relevant differences in populations, interventions and outcomes of the studies entered into the analysis.<br/><sup>c</sup> Downgraded two levels due to serious heterogeneity (I² = 58%). See note <sup>b</sup>.<br/><sup>d</sup> Downgraded one level due to low number of participants recruited and 95% CIs included both no effect and appreciable benefit or appreciable harm, which suggests the risk of very serious imprecision of the results and thus low confidence in their reliability.<br/><sup>e</sup> Downgraded one level due to moderate heterogeneity (I² = 45%). An I<sup>2</sup> statistic between 30% and 60% suggests a moderate risk of inconsistency (unexplained heterogeneity), which may arise from relevant differences in populations, interventions and outcomes of the studies entered into the analysis. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011006-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Selective serotonin reuptake inhibitors (SSRIs) compared to tricyclic antidepressants (TCAs) for people with cancer and depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>SSRIs compared to TCAs for people with cancer and depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with cancer and depression<br/><b>Settings:</b> inpatient and outpatient<br/><b>Intervention:</b> SSRIs<br/><b>Comparison:</b> TCAs </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TCAs</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SSRIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a continuous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy as a continuous outcome (SMD) in the intervention groups was<br/><b>0.08 standard deviations lower</b><br/>(0.34 lower to 0.18 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Efficacy as a dichotomous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b> (0.78 to 1.53 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>199<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>388 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b><br/>(256 to 799) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dropouts due to any cause (acceptability)</b><br/>Follow‐up: 4–12 weeks </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> <br/>(0.53 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>237<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>261 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b><br/>(138 to 339) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>SSRI:</b> selective serotonin reuptake inhibitor; <b>TCA:</b> tricyclic antidepressant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level as no studies described the outcome assessment as blinded. This should be considered a major limitation, which is likely to result in a biased assessment of the intervention effect.<br/><sup>b</sup> Downgraded two levels as very low number of participants recruited (fewer than 100 individuals in both treatment arms) and 95% CIs included both no effect and appreciable benefit or appreciable harm, which suggests the risk of very serious imprecision of the results and thus low confidence in their reliability.<br/><sup>c</sup> Downgraded one level as one study out of three had a high risk of sponsorship bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011006-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mirtazapine compared to tricyclic antidepressants (TCA) for people with cancer and depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mirtazapine compared to placebo for people with cancer and depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cancer and depression<br/><b>Settings:</b> inpatient and outpatient<br/><b>Intervention:</b> mirtazapine<br/><b>Comparison:</b> TCA </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mirtazapine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TCA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a continuous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy as a continuous outcome (MD) in the intervention groups was <b>4.80 lower</b> in the intervention group (9.70 lower to 0.10 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a dichotomous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(46 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81</b> (0.60 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts due to any cause (acceptability)</b><br/>Follow‐up: 4–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><br/>(62 to 662) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.20 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TCA:</b> tricyclic antidepressant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels as overall risk of bias was high according to the RoB 2 assessment, due to missing outcome data.<br/><sup>b</sup> Downgraded two levels as very low number of participants recruited (fewer than 100 individuals in both treatment arms) and 95% CIs included both no effect and appreciable benefit or appreciable harm, which suggests the risk of very serious imprecision of the results and thus low confidence in their reliability.<br/><sup>c</sup> Downgraded one level as overall risk of bias was moderate according to the RoB 2 assessment. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011006-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011006-sec-0009"></div> <section id="CD011006-sec-0010"> <h3 class="title" id="CD011006-sec-0010">Description of the condition</h3> <p>The prevalence of major depression amongst people with cancer has been estimated at around 15% in oncological and haematological settings, with similar rates in palliative care settings. Adding other depressive diagnoses, including dysthymia and minor depression, prevalence rates rise up to 20% in oncological and haematological settings, and up to 25% in palliative care settings (<a href="./references#CD011006-bbs2-0170" title="MitchellAJ , ChanM , BhattiH , HaltonM , GrassiL , JohansenC , et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncology2011;12:160-74.">Mitchell 2011</a>; <a href="./references#CD011006-bbs2-0194" title="RiedlD , SchuesslerG . Prevalence of depression and cancer – a systematic review. Zeitschrift für Psychosomatische Medizin und Psychotherapie2021;1:1-10.">Riedl 2021</a>). However, a precise estimation of the prevalence of depression in people with cancer is difficult due to the influence of many variables, including site and stage of cancer, type of anticancer treatment and diagnostic tools employed (<a href="./references#CD011006-bbs2-0121" title="CarusoR , NanniMG , RibaM , SabatoS , MitchellAJ , CroceE , et al. Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review. Acta Oncologica2017;56(2):146-55. [DOI: 10.1080/0284186X.2016.1266090]">Caruso 2017</a>). </p> <p>Formulating a diagnosis of depression in people affected by serious medical conditions is particularly challenging, as several symptoms of the medical condition may overlap with those described in the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) (<a href="./references#CD011006-bbs2-0111" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington (DC): American Psychiatric Association, 1994.">APA 1994</a>) and the <i>International Classification of Diseases</i> (ICD) (<a href="./references#CD011006-bbs2-0230" title="WHO. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organization, 1992.">WHO 1992</a>) for depression, such as fatigue, weight loss and sleep disturbances (<a href="./references#CD011006-bbs2-0182" title="PanjwaniAA , LiM . Recent trends in the management of depression in persons with cancer. Current Opinion in Psychiatry2021;34(5):448-59.">Panjwani 2021</a>; <a href="./references#CD011006-bbs2-0216" title="ThompsonLM , Bobonis BabiloniaM . Distinguishing depressive symptoms from similar cancer-related somatic symptoms: implications for assessment and management of major depression after breast cancer. Southern Medical Journal2017;110(10):667-72. [DOI: 10.14423/SMJ.0000000000000705]">Thompson 2017</a>). Furthermore, besides physical symptoms, cancer progression is associated with functional, social and relational impairment. Even recurrent thoughts of death might be a normal reaction to a limited life expectancy or to severe pain syndromes (<a href="./references#CD011006-bbs2-0118" title="BreitbartW , RosenfeldB , PessinH , KaimM , Funesti-EschJ , GaliettaM , et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA2000;284(22):2907-11. [PMID: 11147988]">Breitbart 2000</a>; <a href="./references#CD011006-bbs2-0220" title="VehlingS , KissaneDW , LoC , GlaesmerH , HartungTJ , RodinG , et al. The association of demoralization with mental disorders and suicidal ideation in patients with cancer. Cancer2017;123(17):3394-401.">Vehling 2017</a>). It has been reported that atypical depressive symptoms, such as anxiety, despair, fatigue, post‐traumatic stress symptoms, body image distortions, inner restlessness and social withdrawal might be more frequent in this population, and need to be taken into account when depressive symptoms are assessed (<a href="./references#CD011006-bbs2-0119" title="BrenneE , LogeJH , KaasaS , HeitzerE , KnudsenAK , WestonE . Depressed patients with incurable cancer: which depressive symptoms do they experience?Palliative and Supportive Care2013;11(6):491-500. [DOI: 10.1017/S1478951512000909]">Brenne 2013</a>; <a href="./references#CD011006-bbs2-0133" title="Diaz-FrutosD , Baca-GarciaE , García-FoncillasJ , López-CastromanJ . Predictors of psychological distress in advanced cancer patients under palliative treatments. European Journal of Cancer Care2016;25(4):608-15. [DOI: 10.1111/ecc.12521]">Diaz‐Frutos 2016</a>; <a href="./references#CD011006-bbs2-0134" title="EbedeCC , JangY , EscalanteCP . Cancer-related fatigue in cancer survivorship. Medical Clinics of North America2017;101(6):1085-97. [DOI: 10.1016/j.mcna.2017.06.007]">Ebede 2017</a>; <a href="./references#CD011006-bbs2-0232" title="YiJC , SyrjalaKL . Anxiety and depression in cancer survivors. Medical Clinics of North America2017;101(6):1099-113.">Yi 2017</a>). </p> <p>Cancer may increase patients' susceptibility to depression in several ways. First, a reaction to a severe diagnosis and the forthcoming deterioration of health status may constitute a risk factor for depression; second, treatment with immune response modifiers and chemotherapy regimens, and experiencing of metabolic and endocrine alterations, chronic pain and extensive surgical interventions, may represent additional contributing factors (<a href="./references#CD011006-bbs2-0102" title="AdamS , ThongMS , Martin-DienerE , CameyB , Egger HayozC , KonzelmannI , et al. Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors-results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS). Supportive Care in Cancer2021;29(11):6259-69.">Adam 2021</a>; <a href="./references#CD011006-bbs2-0154" title="IrwinMR . Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Current Psychiatry Reports2013;15(11):404. [DOI: 10.1007/s11920-013-0404-1]">Irwin 2013</a>; <a href="./references#CD011006-bbs2-0179" title="OnitiloAA , NietertPJ , EgedeLE . Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. General Hospital Psychiatry2006;28:396-402.">Onitilo 2006</a>; <a href="./references#CD011006-bbs2-0212" title="SoteloJL , MusselmanD , NemeroffC . The biology of depression in cancer and the relationship between depression and cancer progression. International Review of Psychiatry2014;26(1):16-30.">Sotelo 2014</a>; <a href="./references#CD011006-bbs2-0219" title="vanSantenHM , ChemaitillyW , MeachamLR , TonorezosES , Mostoufi-MoabS . Endocrine health in childhood cancer survivors. Pediatric Clinics of North America2020;67(6):1171-86.">van Santen 2020</a>). </p> <p>In people with cancer, depression and other psychiatric comorbidities are responsible for worsened quality of life (<a href="./references#CD011006-bbs2-0112" title="ArrietaO , AnguloLP , Núñez-ValenciaC , Dorantes-GallaretaY , MacedoEO , Martínez-LópezD , et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Annals of Surgical Oncology2013;20(6):1941-8.">Arrieta 2013</a>; <a href="./references#CD011006-bbs2-0183" title="ParkJH , JungYS , KimJY , JoY , BaeSH . Trajectories of health-related quality of life in breast cancer patients. Supportive Care in Cancer2020;28(7):3381-9.">Park 2020</a>; <a href="./references#CD011006-bbs2-0222" title="VyasA , BabcockZ , KogutS . Impact of depression treatment on health-related quality of life among adults with cancer and depression: a population-level analysis. Journal of Cancer Survivorship: Research and Practice2017;11(5):624-33.">Vyas 2017</a>), greater physical symptoms (<a href="./references#CD011006-bbs2-0136" title="FitzgeraldP , LoC , LiM , GaglieseL , ZimmermannC , RodinG . The relationship between depression and physical symptom burden in advanced cancer. BMJ Supportive &amp; Palliative Care2015;5(4):381-8.">Fitzgerald 2015</a>), lower compliance with anticancer treatment (<a href="./references#CD011006-bbs2-0130" title="ColleoniM , MandalaM , PeruzzottiG , RobertsonC , BredartA , GoldhirschA . Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet2000;356(9238):1326-7.">Colleoni 2000</a>; <a href="./references#CD011006-bbs2-0167" title="MausbachBT , SchwabRB , IrwinSA . Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment2015;152(2):239-46.">Mausbach 2015</a>; <a href="./references#CD011006-bbs2-0182" title="PanjwaniAA , LiM . Recent trends in the management of depression in persons with cancer. Current Opinion in Psychiatry2021;34(5):448-59.">Panjwani 2021</a>), prolonged hospitalisation, increased readmissions (<a href="./references#CD011006-bbs2-0176" title="NippRD , El-JawahriA , MoranSM , D'ArpinoSM , JohnsonPC , LageDE , et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer2017;123(23):4720-4727.">Nipp 2017</a>; <a href="./references#CD011006-bbs2-0184" title="PedersonJL , WarkentinLM , MajumdarSR , McAlisterFA . Depressive symptoms are associated with higher rates of readmission or mortality after medical hospitalization: a systematic review and meta-analysis. Journal of hospital medicine2016;11(5):373-80.">Pederson 2016</a>; <a href="./references#CD011006-bbs2-0187" title="PrietoJM , BlanchJ , AtalaJ , CarrerasE , RoviraM , CireraE , et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. Journal of Clinical Oncology2002;20(7):1907-17.">Prieto 2002</a>), delays in treatment and diagnosis (<a href="./references#CD011006-bbs2-0151" title="IglayK , SantorelliML , HirshfieldKM , WilliamsJM , RhoadsGG , LinY , et al. Diagnosis and treatment delays among elderly breast cancer patients with pre-existing mental illness. Breast Cancer Research and Treatment2017;166(1):267-75.">Iglay 2017</a>), disease progression and increased mortality (<a href="./references#CD011006-bbs2-0169" title="McFarlandDC , SaracinoRM , MillerAH , BreitbartW , RosenfeldB , NelsonC . Prognostic implications of depression and inflammation in patients with metastatic lung cancer. Future Oncology2021;17(2):183-96.">McFarland 2021</a>; <a href="./references#CD011006-bbs2-0226" title="WangYH , LiJQ , ShiJF , QueJY , LiuJJ , LappinJM , et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Molecular Psychiatry2020;25(7):1487-99.">Wang 2020</a>), higher suicide risk (<a href="./references#CD011006-bbs2-0197" title="SaadAM , GadMM , Al-HusseiniMJ , AlKhayatMA , RachidA , AlfaarAS , et al. Suicidal death within a year of a cancer diagnosis: a population-based study. Cancer2019;125(6):972-9.">Saad 2019</a>; <a href="./references#CD011006-bbs2-0205" title="ShimEJ , ParkJH . Suicidality and its associated factors in cancer patients: results of a multi-center study in Korea. International Journal of Psychiatry in Medicine2012;43(4):381-403.">Shim 2012</a>), and a greater psychological burden on the family (<a href="./references#CD011006-bbs2-0155" title="JacobsJM , ShafferKM , NippRD , FishbeinJN , MacDonaldJ , El-JawahriA , et al. Distress is interdependent in patients and caregivers with newly diagnosed incurable cancers. Annals of Behavioral Medicine2017;51(4):519-31.">Jacobs 2017</a>; <a href="./references#CD011006-bbs2-0159" title="KimY , SpillersRL . Quality of life of family caregivers at 2 years after a relative's cancer diagnosis. Psycho-oncology2010;19:431-40.">Kim 2010</a>; <a href="./references#CD011006-bbs2-0178" title="OechsleK , UllrichA , MarxG , BenzeG , HeineJ , DickelLM , et al. Psychological burden in family caregivers of patients with advanced cancer at initiation of specialist inpatient palliative care. BMC Palliative Care2019;18(1):102.">Oechsle 2019</a>). Furthermore, depression is likely to be an independent risk factor for cancer mortality (<a href="./references#CD011006-bbs2-0164" title="Lloyd-WilliamsM , ShielsC , TaylorF , DennisM . Depression – an independent predictor of early death inpatients with advanced cancer. Journal of Affective Disorders2009;113:127-32.">Lloyd‐Williams 2009</a>; <a href="./references#CD011006-bbs2-0169" title="McFarlandDC , SaracinoRM , MillerAH , BreitbartW , RosenfeldB , NelsonC . Prognostic implications of depression and inflammation in patients with metastatic lung cancer. Future Oncology2021;17(2):183-96.">McFarland 2021</a>; <a href="./references#CD011006-bbs2-0186" title="PinquartM , DubersteinPR . Depression and cancer mortality: a meta-analysis. Psychological Medicine2010;40(11):1797-810.">Pinquart 2010</a>; <a href="./references#CD011006-bbs2-0226" title="WangYH , LiJQ , ShiJF , QueJY , LiuJJ , LappinJM , et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Molecular Psychiatry2020;25(7):1487-99.">Wang 2020</a>), with estimates as high as a 26% greater mortality rate amongst people with cancer and with depressive symptoms and a 39% higher mortality rate amongst those with a diagnosis of major depression (<a href="./references#CD011006-bbs2-0200" title="SatinJR , LindenW , PhillipsMJ . Depression as a predictor of disease progression and mortality in cancer patients. A meta-analysis. Cancer2009;22:5349-61.">Satin 2009</a>). The effects of depression on mortality may differ by cancer site, being higher in people with lung, gastrointestinal (in particular, pancreatic), and brain cancer, and lower in those with genitourinary and skin cancer (<a href="./references#CD011006-bbs2-0146" title="HartungTJ , BrählerE , FallerH , HärterM , HinzA , JohansenC , et al. The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types. European Journal of Cancer2017;72:46-53. [DOI: 10.1016/j.ejca.2016.11.017]">Hartung 2017</a>; <a href="./references#CD011006-bbs2-0179" title="OnitiloAA , NietertPJ , EgedeLE . Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. General Hospital Psychiatry2006;28:396-402.">Onitilo 2006</a>). However, data are sparse and conflicting on this compelling issue (<a href="./references#CD011006-bbs2-0186" title="PinquartM , DubersteinPR . Depression and cancer mortality: a meta-analysis. Psychological Medicine2010;40(11):1797-810.">Pinquart 2010</a>). As a consequence, individuals with cancer and major depression or depressive symptoms may have radically different features compared with individuals without cancer in terms of underlying risk factors, natural history, outcome and antidepressant treatment response (<a href="./references#CD011006-bbs2-0119" title="BrenneE , LogeJH , KaasaS , HeitzerE , KnudsenAK , WestonE . Depressed patients with incurable cancer: which depressive symptoms do they experience?Palliative and Supportive Care2013;11(6):491-500. [DOI: 10.1017/S1478951512000909]">Brenne 2013</a>; <a href="./references#CD011006-bbs2-0146" title="HartungTJ , BrählerE , FallerH , HärterM , HinzA , JohansenC , et al. The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types. European Journal of Cancer2017;72:46-53. [DOI: 10.1016/j.ejca.2016.11.017]">Hartung 2017</a>; <a href="./references#CD011006-bbs2-0154" title="IrwinMR . Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Current Psychiatry Reports2013;15(11):404. [DOI: 10.1007/s11920-013-0404-1]">Irwin 2013</a>). </p> </section> <section id="CD011006-sec-0011"> <h3 class="title" id="CD011006-sec-0011">Description of the intervention</h3> <p>Antidepressants are the most common psychotropic drugs prescribed in people with depression. Amongst antidepressants, many different agents are available, including tricyclic antidepressants (TCAs); monoamine oxidase inhibitors (MAOIs); selective serotonin reuptake inhibitors (SSRIs); serotonin‐noradrenaline reuptake inhibitors (SNRIs); and other newer agents, such as agomelatine, mirtazapine, reboxetine and bupropion. It has been repeatedly shown that SSRIs are not more effective than TCAs (<a href="./references#CD011006-bbs2-0106" title="AndersonIM , NuttDJ , DeakinJF . Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology (Oxford, England)2000;14(1):3-20.">Anderson 2000</a>; <a href="./references#CD011006-bbs2-0172" title="MottramPG , WilsonK , StroblJJ . Antidepressants for depressed elderly. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD003491. [DOI: 10.1002/14651858.CD003491.pub2]">Mottram 2009</a>), but are better tolerated and safer in overdose than TCAs (<a href="./references#CD011006-bbs2-0106" title="AndersonIM , NuttDJ , DeakinJF . Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology (Oxford, England)2000;14(1):3-20.">Anderson 2000</a>; <a href="./references#CD011006-bbs2-0113" title="BarbuiC , HotopfM . Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. British Journal of Psychiatry2001;178:129-44.">Barbui 2001</a>; <a href="./references#CD011006-bbs2-0127" title="ChockalingamR , GottBM , ConwayCR . Tricyclic antidepressants and monoamine oxidase inhibitors: are they too old for a new look?Handbook of Experimental Pharmacology2019;250:37-48.">Chockalingam 2019</a>; <a href="./references#CD011006-bbs2-0147" title="HenryJA , AlexanderCA , SenerEK . Relative mortality from overdose of antidepressants. BMJ1995;310(6974):221-4.">Henry 1995</a>). </p> <p>In one narrative review covering pharmacological, psychological and psychosocial interventions, <a href="./references#CD011006-bbs2-0163" title="LiM , FitzgeraldP , RodinG . Evidence-based treatment of depression in patients with cancer. Journal of Clinical Oncology2012;30(11):1187-96.">Li 2012</a> reported controversial findings on the effectiveness of antidepressants for the prevention and treatment of depressive symptoms in people with cancer. There were few available studies and the findings were not consistent. It has been suggested that in people with cancer, Canadian Network for Mood and Anxiety Treatments (CANMAT) level I evidence (at least two randomised controlled trials (RCTs) with adequate sample sizes, preferably placebo‐controlled, or meta‐analysis with narrow confidence intervals (CIs), or both) (<a href="./references#CD011006-bbs2-0158" title="KennedySH , LamRW , McIntyreRS , TourjmanSV , BhatV , BlierP , et al, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Canadian Journal of Psychiatry2016;61(9):540-60. [10.1177/0706743716659417]">Kennedy 2016</a>) is available only for mianserin for the treatment of depressive symptoms and for paroxetine for the prevention of new episodes (<a href="./references#CD011006-bbs2-0163" title="LiM , FitzgeraldP , RodinG . Evidence-based treatment of depression in patients with cancer. Journal of Clinical Oncology2012;30(11):1187-96.">Li 2012</a>). One meta‐analysis of the efficacy of psychological and pharmacological interventions by <a href="./references#CD011006-bbs2-0145" title="HartSL , HoytMA , DiefenbachM , AndersonDR , KilbournKM , CraftLL , et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. Journal of the National Cancer Institute2012;104(13):990-1004.">Hart 2012</a> identified only four eligible studies assessing the efficacy of antidepressant drugs. One meta‐analysis found six placebo‐controlled trials and three head‐to‐head trials concerning the treatment of depression in people with cancer at any stage and site (<a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a>). Amongst these studies, there was substantial heterogeneity (i.e. relevant variability of participants, interventions and outcome due to different clinical, methodological and statistical approaches) (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). The meta‐analysis showed an improvement in depressive symptoms in participants treated with antidepressants, with an overall risk ratio (RR) of 1.56 (95% CI 1.07 to 2.28). There was no difference in dropouts between groups. Subgroup analysis failed to identify differences between TCAs and SSRIs, and found that subsyndromal depressive symptoms (i.e. symptoms that do not reach the status of a formal depressive syndrome as it is described by diagnostic manuals, such as DSM or ICD) may similarly improve with antidepressant treatment (<a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a>). Similar findings have been previously shown in physically ill people in one meta‐analytic study (<a href="./references#CD011006-bbs2-0190" title="RaynerL , PriceA , EvansA , ValsrajK , HigginsonIJ , HotopfM . Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007503. [DOI: 10.1002/14651858.CD007503.pub2]">Rayner 2010</a>). </p> <p>A meta‐analysis by <a href="./references#CD011006-bbs2-0223" title="WalkerJ , SawhneyA , Holm HansenC , AhmedS , MartinP , SymeonidesS , et al. Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychological Medicine2014;44(5):897-907.">Walker 2014</a>, which included trials carried out in people with a formal diagnosis of depression, found limited evidence in favour of the use of antidepressant drugs. However, it included only two placebo‐controlled trials, and both used the antidepressant mianserin, which is an agent rarely used in current clinical practice. More recently, Riblet and colleagues, who systematically reviewed the evidence comparing antidepressants and placebo in individuals with any type and stage of cancer and comorbid depression of any severity, retrieved 10 studies suitable for a meta‐analysis on the efficacy of antidepressants (<a href="./references#CD011006-bbs2-0193" title="RibletN , LarsonR , WattsBV , HoltzheimerP . Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. General Hospital Psychiatry2014;36:466-73.">Riblet 2014</a>). They concluded that fluoxetine, paroxetine and mianserin may improve cancer‐related depression. However, one was a quasi‐randomised trial and two trials included participants who were not depressed at baseline. </p> <p><a href="./references#CD011006-bbs2-0191" title="RaynerL , PriceA , EvansA , ValsrajK , HotopfM , HigginsonIJ . Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliative Medicine2011;25(1):36-51.">Rayner 2011a</a> conducted a meta‐analytic study on the efficacy of antidepressants in people receiving palliative care (including cancer and several other life‐threatening illnesses) and with depression (including major depressive disorder, adjustment disorder and dysthymic disorder based on standardised criteria, or according to a score above a certain cut‐off on validated tools, or both). This review detected a beneficial effect associated with antidepressant treatment and suggested that people in palliative care with milder depressive disorders, as well as major depression, may be responsive to antidepressant treatment. These findings were incorporated into European guidelines on the management of depression in palliative cancer care (<a href="./references#CD011006-bbs2-0192" title="RaynerL , PriceA , HotopfM , HigginsonIJ . The development of evidence-based European guidelines on the management of depression in palliative cancer care. European Journal of Cancer2011;47:702-12.">Rayner 2011b</a>), in which use of an antidepressant is recommended, not only in major depression but also in mild depression, if symptoms persist after first‐line treatments have failed (including assessment of the quality of relationships with significant others, psychosocial support, guided self‐help programmes and brief psychological interventions). A four‐year historical prospective cohort study demonstrated that increased antidepressant adherence is associated with decreased all‐cause mortality in a large national cohort of people with cancer (<a href="./references#CD011006-bbs2-0207" title="ShovalG , BalicerRD , FeldmanB , HoshenM , EgerG , WeizmanA , et al. Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: a nationwide cohort study. Depression and Anxiety2019;36(10):921-9.">Shoval 2019</a>). However, there is still a lack of evidence whether antidepressants are all similarly effective in this population. </p> </section> <section id="CD011006-sec-0012"> <h3 class="title" id="CD011006-sec-0012">How the intervention might work</h3> <p>Antidepressants are a heterogeneous class of drugs, in which a common mechanism of action is not traceable. Their therapeutic action may be related to their ability to affect serotonin, noradrenaline and dopamine neurotransmission systems, according to the broadly studied theory about monoamine dysregulation as the key neurophysiological event underlying mood disorders. However, alternative mechanisms have been shown, making progressively clearer the complexity of interactions between several systems on which the action of these drugs rely. For instance, current research on new antidepressant drugs focuses on affecting mechanisms related to glutamate (<a href="./references#CD011006-bbs2-0162" title="LapidusKA , SoleimaniL , MurroughJW . Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatric Disease and Treatment2013;9:1101-12. [DOI: 10.2147/NDT.S36689]">Lapidus 2013</a>; <a href="./references#CD011006-bbs2-0173" title="MurroughJW , AbdallahCG , MathewSJ . Targeting glutamate signalling in depression: progress and prospects. Nature reviews. Drug discovery2017;16(7):472-86.">Murrough 2017</a>) and melatonin transmission (<a href="./references#CD011006-bbs2-0148" title="HickieIB , RogersNL . Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet2011;378:621-31. [DOI: 10.1016/S0140-6736(11)60095-0]">Hickie 2011</a>), neural proliferation and plasticity in limbic areas (<a href="./references#CD011006-bbs2-0185" title="Pilar-CuéllarF , VidalR , DíazA , CastroE , dos AnjosS , Pascual-BrazoJ , et al. Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. Neural Plasticity2013;2013:1-21. [DOI: 10.1155/2013/537265]">Pilar‐Cuéllar 2013</a>), and endocrine system activities (hypothalamic‐pituitary‐adrenal axis in particular) (<a href="./references#CD011006-bbs2-0199" title="SarubinN , NothdurfterC , SchmotzC , WimmerAM , TrummerJ , LiebM , et al. Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. Psychoneuroendocrinology2014;39:141-51. [DOI: 10.1016/j.psyneuen.2013.10.008]">Sarubin 2014</a>), as well as antioxidant, anti‐inflammatory and immunological pathways (<a href="./references#CD011006-bbs2-0141" title="GobinV , vanSteendamK , DenysD , DeforceD . Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. International immunopharmacology2014;20(1):148-56.">Gobin 2014</a>; <a href="./references#CD011006-bbs2-0165" title="LoprestiAL , HoodSD , DrummondPD . Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. Journal of Psychopharmacology2012;26(12):1512-24. [DOI: 10.1177/0269881112458732]">Lopresti 2012</a>). </p> <p>The extent to which each of these components can contribute to the dysregulation of the brain's homeostatic system could vary extensively amongst different individuals and also with several biological, environmental and psychological factors (<a href="./references#CD011006-bbs2-0204" title="SheltonRC . The molecular neurobiology of depression. Psychiatric Clinics of North America2007;30(1):1-11.">Shelton 2007</a>). For this reason, even if the efficacy of antidepressants has been proven for some types of depressive conditions, we cannot assume these data to be reliable in the same way for people with cancer, for whom several further factors may be involved in the pathogenesis (including psychological, immunological and metabolic factors, as well as pain and highly distressing treatments). Some authors have suggested a possible beneficial effect of antidepressants in cancer biology (<a href="./references#CD011006-bbs2-0103" title="AhmadianE , EftekhariA , BabaeiH , NayebiAM , EghbalMA . Anti-cancer effects of citalopram on hepatocellular carcinoma cells occur via cytochrome C release and the activation of NF-kB. Anticancer Agents in Medicinal Chemistry2017;17(11):1570-7. [DOI: 10.2174/1871520617666170327155930]">Ahmadian 2017</a>; <a href="./references#CD011006-bbs2-0126" title="ChanHL , ChiuWC , ChenVC , HuangKY , WangTN , LeeY , et al. SSRIs associated with decreased risk of hepatocellular carcinoma: a population-based case-control study. Psycho-oncology2018;27(1):187-92. [DOI: 10.1002/pon.4493]">Chan 2017</a>; <a href="./references#CD011006-bbs2-0140" title="Gil-AdI , ZolokovA , LomnitskiL , TalerM , BarM , LuriaD , et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. International Journal of Oncology2008;33(2):277-86.">Gil‐Ad 2008</a>; <a href="./references#CD011006-bbs2-0211" title="SongY , YangX , YuB . Repurposing antidepressants for anticancer drug discovery. Drug Discovery Today2021;1:1-10.">Song 2021</a>; <a href="./references#CD011006-bbs2-0235" title="ZingoneA , BrownD , BowmanED , VidalO , SageJ , NealJ , et al. Relationship between anti-depressant use and lung cancer survival. Cancer Treatment and Research Communications2017;10:33-9. [DOI: 10.1016/j.ctarc.2017.01.001]">Zingone 2017</a>). However, these findings are largely explorative and need to be further investigated; and it is not clear whether the effect of antidepressants may differ according to the specific cancer type or site, or both. Few systematic reviews have explored this issue, retrieving only small numbers of studies from which to draw conclusions (<a href="./references#CD011006-bbs2-0122" title="CarvalhoAF , HyphantisT , SalesPM , Soeiro-de-SouzaMG , MacêdoDS , ChaDS , et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treatment Reviews 40;3:349-55. [DOI: 10.1016/j.ctrv.2013.09.009]">Carvalho 2014</a>; <a href="./references#CD011006-bbs2-0223" title="WalkerJ , SawhneyA , Holm HansenC , AhmedS , MartinP , SymeonidesS , et al. Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychological Medicine2014;44(5):897-907.">Walker 2014</a>). </p> <p>In most cases, antidepressant dose should be gradually titrated and it can be some weeks before the treatment takes effect. Antidepressants may require adjustment over time to ensure an appropriate dose is given. Moreover, it has been highlighted that compliance represents a relevant factor for an antidepressant's efficacy (<a href="./references#CD011006-bbs2-0128" title="ChongWW , AslaniP , ChenTF . Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. International Journal of Clinical Practice2011;65(9):954-75.">Chong 2011</a>; <a href="./references#CD011006-bbs2-0221" title="VergouwenAC , BakkerA , KatonWJ , VerheijTJ , KoerselmanF . Improving adherence to antidepressants: a systematic review of interventions. Journal of Clinical Psychiatry2003;64(12):1415-20. [PMID: 14728101]">Vergouwen 2003</a>). </p> </section> <section id="CD011006-sec-0013"> <h3 class="title" id="CD011006-sec-0013">Why it is important to do this review</h3> <p>Providing better interventions for people with cancer and depressive symptoms is an important goal. Single pharmacological, psychological and physical interventions are not an exhaustive response for such a complex and multifaceted condition, which is likely to benefit from integrated, multicomponent approaches (<a href="./references#CD011006-bbs2-0108" title="AnwarN , KuppiliPP , BalharaYP . Depression and physical non-communicable diseases: the need for an integrated approach. WHO South-East Asia Journal of Public Health2017;6(1):12-7. [DOI: 10.4103/2224-3151.206158.]">Anwar 2017</a>; <a href="./references#CD011006-bbs2-0203" title="SharpeM , WalkerJ , Holm HansenC , MartinP , SymeonidesS , GourleyC , et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. Lancet2014;384(9948):1099-108. [10.1016/S0140-6736(14)61231-9]">Sharpe 2014</a>). With this in mind, a Cochrane systematic review on the efficacy, tolerability and acceptability of antidepressants is needed in addition to existing Cochrane systematic reviews on psychotherapy (<a href="./references#CD011006-bbs2-0168" title="McCaughanE , ParahooK , HueterI , NorthouseL , BradburyI . Online support groups for women with breast cancer. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD011652. [DOI: 10.1002/14651858.CD011652.pub2]">McCaughan 2017</a>), psychosocial (<a href="./references#CD011006-bbs2-0139" title="GalwayK , BlackA , CantwellM , CardwellCR , MillsM , DonnellyM . Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD007064. [DOI: 10.1002/14651858.CD007064.pub2]">Galway 2012</a>; <a href="./references#CD011006-bbs2-0202" title="SempleC , ParahooK , NormanA , McCaughanE , HumphrisG , MillsM . Psychosocial interventions for patients with head and neck cancer. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD009441. [DOI: 10.1002/14651858.CD009441.pub2]">Semple 2013</a>), physical (<a href="./references#CD011006-bbs2-0137" title="FurmaniakAC , MenigM , MarkesMH . Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD005001. [DOI: 10.1002/14651858.CD005001.pub3]">Furmaniak 2016</a>; <a href="./references#CD011006-bbs2-0206" title="ShinES , SeoKH , LeeSH , JangJE , JungYM , KimMJ , et al. Massage with or without aromatherapy for symptom relief in people with cancer. Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009873. [DOI: 10.1002/14651858.CD009873]">Shin 2016</a>) and complementary interventions (<a href="./references#CD011006-bbs2-0117" title="BradtJ , ShimM , GoodillSW . Dance/movement therapy for improving psychological and physical outcomes in cancer patients. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD007103. [DOI: 10.1002/14651858.CD007103.pub3]">Bradt 2015</a>; <a href="./references#CD011006-bbs2-0131" title="CramerH , LaucheR , KloseP , LangeS , LanghorstJ , DobosGJ . Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD010802. [DOI: 10.1002/14651858.CD010802.pub2]">Cramer 2017</a>). </p> <p>One systematic review by <a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a> included participants with depressive disorder and subsyndromal depressive symptoms and identified nine RCTs for inclusion. It showed antidepressants to be superior to placebo. However, the review included only trials in published in English, they did not seek unpublished studies, and they excluded studies with depression as a secondary outcome. Further, the authors performed a meta‐analysis on dichotomous data only. Another review included people with a diagnosis of depressive disorder, subsyndromal depressive symptoms, and people without an assessment of depressive symptoms at baseline, provided that they received antidepressant treatments for emotionally distressing cancer‐related manifestations (such as fatigue, insomnia, asthenia or cancer pain) (<a href="./references#CD011006-bbs2-0180" title="OstuzziG , BendaL , CostaE , BarbuiC . Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis. Cancer Treatment Reviews2015;41(8):714-24. [10.1016/j.ctrv.2015.06.003]">Ostuzzi 2015a</a>). The meta‐analysis showed a beneficial effect of antidepressants over placebo in treating depressive symptoms as a whole, and the positive effect remained when considering separately participants with a formal diagnosis of major depression or depressive symptoms at baseline, and participants for whom antidepressant use was related to other distressing cancer‐related symptoms. In addition, antidepressants were effective in improving quality of life. </p> <p>Considering these limitations and that available systematic reviews provide contrasting findings (<a href="./references#CD011006-bbs2-0145" title="HartSL , HoytMA , DiefenbachM , AndersonDR , KilbournKM , CraftLL , et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. Journal of the National Cancer Institute2012;104(13):990-1004.">Hart 2012</a>; <a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a>; <a href="./references#CD011006-bbs2-0163" title="LiM , FitzgeraldP , RodinG . Evidence-based treatment of depression in patients with cancer. Journal of Clinical Oncology2012;30(11):1187-96.">Li 2012</a>; <a href="./references#CD011006-bbs2-0195" title="RodinG , LloydN , KatzM , GreenE , MackayJA , WongRK , Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The treatment of depression in cancer patients: a systematic review. Supportive Care in Cancer2007;15(2):123-36.">Rodin 2007</a>), there is still uncertainty as to the true efficacy of antidepressants (<a href="./references#CD011006-bbs2-0196" title="RooneyA , GrantR . Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database of Systematic Reviews2013, Issue 5. Art. No: CD006932. [DOI: 10.1002/14651858.CD006932.pub3]">Rooney 2013</a>; <a href="./references#CD011006-bbs2-0223" title="WalkerJ , SawhneyA , Holm HansenC , AhmedS , MartinP , SymeonidesS , et al. Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychological Medicine2014;44(5):897-907.">Walker 2014</a>). Moreover, most of the previous reviews focused on elevated depressive symptoms (<a href="./references#CD011006-bbs2-0145" title="HartSL , HoytMA , DiefenbachM , AndersonDR , KilbournKM , CraftLL , et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. Journal of the National Cancer Institute2012;104(13):990-1004.">Hart 2012</a>), or major depression (<a href="./references#CD011006-bbs2-0153" title="IovienoN , TedeschiniE , AmeralVE , RigatelliM , PapakostasGI . Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. International Clinical Psychopharmacology2011;26:69-74.">Iovieno 2011</a>; <a href="./references#CD011006-bbs2-0174" title="NgCG , BoksMP , ZainalNZ , deWitNJ . The prevalence and pharmacotherapy of depression in cancer patients. Journal of Affective Disorders2011;131:1-7.">Ng 2011</a>; <a href="./references#CD011006-bbs2-0223" title="WalkerJ , SawhneyA , Holm HansenC , AhmedS , MartinP , SymeonidesS , et al. Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychological Medicine2014;44(5):897-907.">Walker 2014</a>), while current findings suggest that depressive symptoms, even in subsyndromal manifestations, could represent an independent risk factor for the burden of disease (<a href="./references#CD011006-bbs2-0112" title="ArrietaO , AnguloLP , Núñez-ValenciaC , Dorantes-GallaretaY , MacedoEO , Martínez-LópezD , et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Annals of Surgical Oncology2013;20(6):1941-8.">Arrieta 2013</a>; <a href="./references#CD011006-bbs2-0119" title="BrenneE , LogeJH , KaasaS , HeitzerE , KnudsenAK , WestonE . Depressed patients with incurable cancer: which depressive symptoms do they experience?Palliative and Supportive Care2013;11(6):491-500. [DOI: 10.1017/S1478951512000909]">Brenne 2013</a>; <a href="./references#CD011006-bbs2-0186" title="PinquartM , DubersteinPR . Depression and cancer mortality: a meta-analysis. Psychological Medicine2010;40(11):1797-810.">Pinquart 2010</a>; <a href="./references#CD011006-bbs2-0200" title="SatinJR , LindenW , PhillipsMJ . Depression as a predictor of disease progression and mortality in cancer patients. A meta-analysis. Cancer2009;22:5349-61.">Satin 2009</a>). Although the efficacy of antidepressants in minor depression, dysthymia and adjustment disorder is still not clear (<a href="./references#CD011006-bbs2-0114" title="BarbuiC , CiprianiA , PatelV , Ayuso-MateosJL , vanOmmerenM . Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. British Journal of Psychiatry2011;198(1):11-6.">Barbui 2011</a>; <a href="./references#CD011006-bbs2-0123" title="CaseyP , BaileyS . Adjustment disorders: the state of the art. World Psychiatry2011;10(1):11-8.">Casey 2011</a>; <a href="./references#CD011006-bbs2-0208" title="Silva de LimaM , HotophM , WesselyS . The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychological Medicine1999;29(6):1273-89.">Silva de Lima 1999</a>; <a href="./references#CD011006-bbs2-0209" title="Silva de LimaM , MoncrieffJ , SoaresB . Drugs versus placebo for dysthymia. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001130. [DOI: 10.1002/14651858.CD001130]">Silva de Lima 2005</a>), different authors suggest that antidepressants are effective in people with a severe medical illness (including cancer), even for subthreshold depressive symptoms (<a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a>; <a href="./references#CD011006-bbs2-0190" title="RaynerL , PriceA , EvansA , ValsrajK , HigginsonIJ , HotopfM . Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007503. [DOI: 10.1002/14651858.CD007503.pub2]">Rayner 2010</a>; <a href="./references#CD011006-bbs2-0191" title="RaynerL , PriceA , EvansA , ValsrajK , HotopfM , HigginsonIJ . Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliative Medicine2011;25(1):36-51.">Rayner 2011a</a>). </p> <p>Based on this evidence we carried out a systematic review (<a href="./references#CD011006-bbs2-0237" title="OstuzziG , MatchamF , DauchyS , BarbuiC , HotopfM . Antidepressants for the treatment of depression in people with cancer. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD011006. [DOI: 10.1002/14651858.CD011006.pub2]">Ostuzzi 2015b</a>). In this previous version of the review, we found no differences between antidepressants (as a class) and placebo in treating depressive symptoms (very low‐certainty evidence). Similarly, we found no differences between SSRIs and TCAs (very low‐certainty evidence). In this update, we sought to include new relevant studies or to retrieve new data from studies that were previously awaiting classification. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011006-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011006-sec-0014"></div> <p>To evaluate the efficacy, tolerability and acceptability of antidepressants for treating depressive symptoms in adults (aged 18 years or older) with cancer (any site and stage). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011006-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011006-sec-0015"></div> <section id="CD011006-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011006-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs. We excluded studies using quasi‐random methods. We included studies published in any language. </p> </section> <section id="CD011006-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults (aged 18 years or older) with any primary diagnosis of cancer (confirmed with appropriate clinical and instrumental assessment) and major depressive disorder, adjustment disorder, dysthymic disorder or depressive symptoms in the absence of a formal diagnosis of major depression. Differently from the previous version of this review, we also included studies where, although a formal diagnosis of depression was not reported, the mean baseline score of validated rating scales measuring depression was consistent with depression of at least moderate severity. The cut‐off scores we used were: </p> <p> <ul id="CD011006-list-0001"> <li> <p>18 or greater using the Hamilton Rating Scale for Depression (HAM‐D) (<a href="./references#CD011006-bbs2-0132" title="CusinC , YangH , YeungA , FavaM . Chapter 2. Rating scales for depression. In: BaerL , BlaisMA , editors(s). Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. Current Clinical Psychology. New York (NY): Humana Press, 2010:7-36. [PDF: rehabilitationpsychologist.org/resources/Handbook-of-Clinical-Rating-Scales-and-Assessment-in-Psychiatry-and-Mental-Health.pdf]">Cusin 2010</a>); </p> </li> <li> <p>21 or greater using the Beck Depression Inventory (BDI) (<a href="./references#CD011006-bbs2-0225" title="WangYP , GorensteinC . Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Revista Brasileira de Psiquiatria2013;35(4):416-31.">Wang 2013</a>); </p> </li> <li> <p>22 or greater using the Montgomery‐Åsberg Depression Rating Scale (MADRS) (<a href="./references#CD011006-bbs2-0166" title="MassonSC , TejaniAM . Minimum clinically important differences identified for commonly used depression rating scales. Journal of Clinical Epidemiology2013;66(7):805-7. [DOI: 10.1016/j.jclinepi.2013.01.010] [PMID: 23618794]">Masson 2013</a>). </p> </li> </ul> </p> <p>We included participants receiving antidepressants for other indications (e.g. fatigue, neuropathic pain, hot flushes, etc.) only if the criterion of being affected by one of the above‐mentioned depressive conditions was met at the time of enrolment. </p> <p>For studies including a diagnosis of depression, we included any standardised criteria. Most recent studies use DSM‐IV (<a href="./references#CD011006-bbs2-0111" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington (DC): American Psychiatric Association, 1994.">APA 1994</a>), or ICD‐10 (<a href="./references#CD011006-bbs2-0230" title="WHO. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organization, 1992.">WHO 1992</a>) criteria. Older studies use ICD‐9 (<a href="./references#CD011006-bbs2-0229" title="WHO. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9). Geneva: World Health Organization, 1978.">WHO 1978</a>), DSM‐III (<a href="./references#CD011006-bbs2-0109" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edition. Washington (DC): American Psychiatric Association, 1980.">APA 1980</a>) or DSM‐ III‐R (<a href="./references#CD011006-bbs2-0110" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd revised edition. Washington (DC): American Psychiatric Association, 1987.">APA 1987</a>), or other diagnostic systems. For studies including depressive symptoms in the absence of a formal diagnosis of major depression, we only included those employing standardised criteria to measure depressive symptoms and with evidence of adequate validity and reliability. Most recent studies use the HAM‐D (<a href="./references#CD011006-bbs2-0144" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56-62.">Hamilton 1960</a>), the BDI (<a href="./references#CD011006-bbs2-0115" title="BeckAT , WardCH , MendelsonM , MockJ , ErbaughJ . An inventory for measuring depression. Archives of General Psychiatry1961;4:561-71.">Beck 1961</a>), the MADRS (<a href="./references#CD011006-bbs2-0171" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382-9.">Montgomery 1979</a>), or the Hospital Anxiety and Depression Scale (HADS) (<a href="./references#CD011006-bbs2-0234" title="ZigmondAS , SnaithRP . The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica1983;67(6):361-70.">Zigmond 1983</a>). </p> </section> <section id="CD011006-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following antidepressants, reported in the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) Index (updated to February 2022) from the World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology website (<a href="http://www.whocc.no" target="_blank">www.whocc.no</a>): </p> <p> <ul id="CD011006-list-0002"> <li> <p>non‐selective MAOIs, such as amitriptyline, desipramine, imipramine, imipramine oxide, nortriptyline, clomipramine, dosulepine, doxepin, opipramol, trimipramine, lofepramine, dibenzepin, protriptyline, iprindole, melitracen, butriptyline, amoxapine, dimetacrine, amineptine, maprotiline, quinupramine; </p> </li> <li> <p>SSRIs, such as fluoxetine, fluvoxamine, citalopram, escitalopram, paroxetine, sertraline, alaproclate, etoperidone, zimelidine; </p> </li> <li> <p>monoamine oxidase A inhibitors, such as moclobemide, toloxatone;</p> </li> <li> <p>non‐selective MAOIs, such as isocarboxazid, nialamide, phenelzine, tranylcypromine, iproniazide, iproclozide; </p> </li> <li> <p>SNRIs such as venlafaxine, duloxetine, desvenlafaxine, milnacipran, levomilnacipran;</p> </li> <li> <p>any newer antidepressant and any other non‐conventional antidepressive agents, such as mianserin, trazodone, nefazodone, mirtazapine, bupropion, reboxetine, agomelatine, oxitriptan, tryptophan, nomifensine, minaprine, bifemelane, viloxazine, oxaflozane, medifoxamine, tianeptine, pivagabine, gepirone, vilazodone, Hyperici herba, vortioxetine, esketamine. </p> </li> </ul> </p> <p>The comparison group was placebo or any other antidepressants (head‐to‐head comparisons), or both. </p> <p>We excluded studies that compared antidepressants were compared with another type of psychopharmacological agent (i.e. psychostimulants, anxiolytics, anticonvulsants, antipsychotics or mood stabilisers). </p> </section> <section id="CD011006-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD011006-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD011006-sec-0022"> <h6 class="title">Efficacy as a continuous outcome</h6> <p>We extracted and analysed group mean scores at different time points and, if these were not available, group mean change scores, using the HAM‐D), MADRS or Clinical Global Impression Rating scale (CGI), or on any other depression rating scale with evidence of adequate validity and reliability, as follows: </p> <p> <ul id="CD011006-list-0003"> <li> <p>early response: between one and four weeks, giving preference to the time point closest to two weeks; </p> </li> <li> <p>acute phase treatment response: between six and 12 weeks, giving preference to the time point given in the original trial as the study endpoint; </p> </li> <li> <p>follow‐up response: after 12 weeks, giving preference to the time point closest to 24 weeks. </p> </li> </ul> </p> <p>The acute phase treatment response (between six and 12 weeks) was our primary outcome of interest. If the acute phase treatment response was reported, we then reported early response and follow‐up response as secondary outcomes. </p> </section> </section> <section id="CD011006-sec-0023"> <h5 class="title">Secondary outcomes</h5> <section id="CD011006-sec-0024"> <h6 class="title">Efficacy as a dichotomous outcome</h6> <p>Treatment responders during the 'acute phase' (between six and 12 weeks): proportion of participants showing a reduction of at least 50% on the HAM‐D or MADRS or any other depression scale (e.g. the BDI or the Center for Epidemiologic Studies Depression Scale (CES‐D)), or who were 'much or very much improved' (score 1 or 2) on the Clinical Global Impression – Improvement (CGI‐I) scale, or the proportion of participants who improved using any other prespecified criterion. </p> </section> <section id="CD011006-sec-0025"> <h6 class="title">Social adjustment</h6> <p>Mean scores on social adjustment rating scales (e.g. Global Assessment of Functioning (GAF)), as defined by each of the studies, during the 'acute phase' (between six and 12 weeks). </p> </section> <section id="CD011006-sec-0026"> <h6 class="title">Health‐related quality of life</h6> <p>Mean scores on quality‐of‐life rating scales during the 'acute phase' (between six and 12 weeks). We gave preference to illness‐specific quality of life measures, such as the European Organisation for Research and Treatment into Cancer Quality of Life Questionnaire‐30 (EORTC QLQ‐C30) (<a href="./references#CD011006-bbs2-0101" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365-75.">Aaronson 1993</a>), the Functional Assessment of Cancer Therapy (FACT) scale (<a href="./references#CD011006-bbs2-0124" title="CellaD , TulskyD , GrayG , SarafianB , LinnE , BonomiA , et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology1993;11:570-9.">Cella 1993</a>), and the 36‐item Short Form Health Survey (SF‐36) (<a href="./references#CD011006-bbs2-0227" title="WareJB , BrookRH , WilliamsKN , StewartAL , Davies-AveryA . Conceptualisation and Measurement of Health for Adults in the Health Insurance Study. Vol. 1. Santa Monica (CA): Rand Corporation, 1980. [R-1987/1-HEW]">Ware 1980</a>; <a href="./references#CD011006-bbs2-0228" title="WareJE , SherbourneCD . The MOS 36-item short-form health survey (SF-36) 1: conceptual framework and item selection. Medical Care1992;30:473-83.">Ware 1992</a>). When such tools were not employed, we used a general health‐related quality of life measure with evidence of adequate validity and reliability, as defined by each of the trial </p> </section> <section id="CD011006-sec-0027"> <h6 class="title">Dropouts</h6> <p> <ul id="CD011006-list-0004"> <li> <p>Number of participants who dropped out during the trial as a proportion of the total number randomised (total dropout rate, also referred as 'acceptability'). </p> </li> <li> <p>Number of participants who dropped out due to inefficacy during the trial as a proportion of the total number randomised (dropout rates due to inefficacy). </p> </li> <li> <p>Number of participants who dropped out due to adverse effects during the trial as a proportion of the total number randomised (dropout rates due to adverse effects, also referred as 'tolerability'). </p> </li> </ul> </p> <p>We extracted dropouts at trial endpoint only.</p> </section> </section> </section> </section> <section id="CD011006-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011006-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic bibliographic databases: the Cochrane Central Register of Controlled Trials (CENTRAL, 2022, Issue 11) in the Cochrane Library (searched 24 November 2022) (<a href="./appendices#CD011006-sec-0113">Appendix 1</a>), MEDLINE Ovid (1946 to November 2022) (<a href="./appendices#CD011006-sec-0114">Appendix 2</a>), Embase Ovid (1980 to November 2022) (<a href="./appendices#CD011006-sec-0115">Appendix 3</a>), and PsycINFO Ovid (1987 to November 2022) (<a href="./appendices#CD011006-sec-0116">Appendix 4</a>). </p> </section> <section id="CD011006-sec-0030"> <h4 class="title">Searching other resources</h4> <section id="CD011006-sec-0031"> <h5 class="title">Handsearches</h5> <p>We handsearched the trial databases of the following drug‐approving agencies for published, unpublished and ongoing controlled trials: the US FDA (<a href="http://www.fda.gov" target="_blank">www.fda.gov</a>), the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK (<a href="http://www.mhra.gov.uk/" target="_blank">www.mhra.gov.uk/</a>), the European Medicines Agency (EMA) in the EU (<a href="http://www.ema.europa.eu" target="_blank">www.ema.europa.eu</a>), the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan (<a href="http://www.pmda.go.jp/english/" target="_blank">www.pmda.go.jp/english/</a>), and the Therapeutic Goods Administration (TGA) in Australia (<a href="http://www.tga.gov.au/" target="_blank">www.tga.gov.au/</a>). </p> <p>We additionally searched the following trial registers: ClinicalTrials.gov in the US (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>), ISRCTN and National Research Register in the UK (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>), UMIN‐CTR in Japan (<a href="http://www.umin.ac.jp/ctr/" target="_blank">www.umin.ac.jp/ctr/</a>), the ANZCTR in Australia and New Zealand (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au/</a>), the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>), and the International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA) Clinical Trials Portal (<a href="https://www.ifpma.org/tag/clinical-trials/" target="_blank">www.ifpma.org/tag/clinical-trials/</a>). </p> <p>We also handsearched appropriate journals and conference proceedings relating to depression treatment in people with cancer. We handsearched the websites of the most relevant pharmaceutical companies producing antidepressants, such as GlaxoSmithKline (<a href="http://www.gsk-clinicalstudyregister.com/" target="_blank">www.gsk-clinicalstudyregister.com/</a>), Sanofi (<a href="http://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/" target="_blank">www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/</a>), Janssen (<a href="http://www.janssen.com/clinical-trials" target="_blank">www.janssen.com/clinical-trials</a>), Lundbeck (<a href="https://www.lundbeck.com/global/our-science/clinical-trials" target="_blank">www.lundbeck.com/global/our-science/clinical-trials</a>), Pfizer (<a href="https://www.pfizer.co.uk/clinical-trials" target="_blank">www.pfizer.co.uk/clinical-trials</a>), Abbott (<a href="http://www.abbott.com/policies/clinical-trials.html" target="_blank">www.abbott.com/policies/clinical-trials.html</a>), Lilly (<a href="http://www.lillytrials.com/" target="_blank">www.lillytrials.com/</a>), and Merck (<a href="http://www.merck.com/research/discovery-and-development/clinical-development/home.html" target="_blank">www.merck.com/research/discovery-and-development/clinical-development/home.html</a>) for published, unpublished and ongoing controlled trials. </p> <p>We searched reference lists of included trials and other relevant studies.</p> </section> <section id="CD011006-sec-0032"> <h5 class="title">Personal communication</h5> <p>We contacted the authors of unpublished studies. Only one author provided data from one unpublished study. </p> </section> </section> </section> <section id="CD011006-sec-0033"> <h3 class="title" id="CD011006-sec-0033">Data collection and analysis</h3> <section id="CD011006-sec-0034"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to a reference management database (Endnote) and removed duplicates. Two review authors (GV and BC) independently examined the remaining references. We excluded those studies that clearly did not meet the inclusion criteria, and we obtained copies of the full text of potentially relevant references. Two review authors (GV and BC) independently assessed the eligibility of retrieved studies. We resolved disagreements by discussion between the two review authors and, if necessary, with a third review author (GO). We documented reasons for exclusion. We collated multiple reports of the same studies to ensure that no data were included in the meta‐analysis more than once. </p> </section> <section id="CD011006-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (GV and BC), working independently and in duplicate, extracted data from the included studies using a data collection sheet (see <a href="./appendices#CD011006-sec-0117">Appendix 5</a>), which was developed in accordance with recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>; Chapter 7). If the trial was a three (or more)‐armed trial involving a placebo arm, we also extracted data from the placebo arm. </p> <p>Data included:</p> <p> <ul id="CD011006-list-0005"> <li> <p>first author, year and journal;</p> </li> <li> <p>methodological features (study design, randomisation, blinding and allocation concealment, follow‐up period); </p> </li> <li> <p>participant characteristics (gender, age, study setting, number of participants randomised to each arm, depression diagnosis, previous history of depression, cancer site and stage, cancer treatment); </p> </li> <li> <p>intervention details (antidepressant and other interventions employed, dosage range, mean daily dosage prescribed); </p> </li> <li> <p>outcome measures for each time point of interest. Continuous measures encompassed mean scores of rating scales, standard deviation (SD) or standard error (SE); dichotomous measures were endpoint response rate and dropout rate, which were calculated on a strict intention‐to‐treat (ITT) basis; </p> </li> <li> <p>cost analysis (estimates of the cost of resources employed to perform the trial);</p> </li> <li> <p>presence of sponsorship by a drug company.</p> </li> </ul> </p> <p>Alongside the data that contributed to meta‐analysis, we collected characteristics of participants, settings, interventions and methodological approaches, in order to provide an overall view of the available evidence on this topic (see <a href="#CD011006-sec-0051">Description of studies</a>), as well as to perform an accurate assessment of the risk of bias (see <a href="#CD011006-sec-0062">Risk of bias in included studies</a>). These elements provided a crucial contribution to the discussion, with particular regards to the clinical applicability of the results of the study (see <a href="#CD011006-sec-0103">Overall completeness and applicability of evidence</a>; <a href="#CD011006-sec-0108">Implications for practice</a>). </p> </section> <section id="CD011006-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (GV and GO) independently assessed the risk of bias of all included studies with the effect of assignment to intervention in accordance with Cochrane's RoB 2 tool (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>; <a href="./references#CD011006-bbs2-0214" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898. PMID: 31462531.]">Sterne 2019</a>, Chapter 8), which includes the following domains (<a href="./appendices#CD011006-sec-0118">Appendix 6</a>) (the previous version of the review used the RoB 1 tool). </p> <p> <ul id="CD011006-list-0006"> <li> <p>Bias in the randomisation process</p> </li> <li> <p>Bias from deviations from the intended interventions</p> </li> <li> <p>Bias from missing outcome data</p> </li> <li> <p>Bias in measurement of the outcome</p> </li> <li> <p>Bias in the selection of reported results</p> </li> </ul> </p> <p>The analysis did not include any cluster or cross‐over RCTs. Risk of Bias 2 does not assess the overall quality of the studies, but it assesses the risk of bias of a specific study outcome at a specific time point (six to 12 weeks). </p> <p>We performed ROB 2 assessment for:</p> <p> <ul id="CD011006-list-0007"> <li> <p>efficacy at six to 12 weeks as a continuous variable;</p> </li> <li> <p>efficacy at six to 12 weeks as a dichotomous variable;</p> </li> <li> <p>acceptability at study endpoint (up to 24 weeks).</p> </li> </ul> </p> <p>To determine the risk of bias for each outcome we evaluated the presence of sufficient information and the likelihood of potential bias in each domain. Two review authors (GV and BC) rated each criterion as 'low risk of bias,' 'high risk of bias' or 'some concerns' using the signalling questions to decide on the overall risk of bias for each domain and how we determined the overall risk of bias for each result. If there were inadequate details of methodological characteristics of studies, we contacted the study authors to request further information. If the review authors disagreed on ratings, we made the final rating by consensus with the involvement (if necessary) of a third review author (GO or CB). We used the RoB 2 Excel tool to manage the assessment and we discussed and interpreted the results of meta‐analysis in light of the findings and with respect to the risk of bias. </p> </section> <section id="CD011006-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011006-sec-0038"> <h5 class="title">Continuous data</h5> <p>We evaluated the efficacy of treatments as a continuous measure, namely the group mean scores on depression rating scales at the acute phase (between six and 12 weeks). We employed other continuous data for some secondary outcomes, namely efficacy at early response (between one and four weeks), efficacy at follow‐up response (after 12 weeks), social adjustment and health‐related quality of life. </p> </section> <section id="CD011006-sec-0039"> <h5 class="title">Dichotomous data</h5> <p>We employed dichotomous data for some secondary outcomes, namely efficacy as the number of treatment responders at the acute phase (between six and 12 weeks), and the proportion of dropouts. </p> </section> </section> <section id="CD011006-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011006-sec-0041"> <h5 class="title">Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, the participants can differ systematically from their initial state, even despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD011006-bbs2-0135" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). Both effects are very likely in major depression, thus we planned to use only data from the first phase of cross‐over trials. </p> </section> <section id="CD011006-sec-0042"> <h5 class="title">Cluster‐randomised trials</h5> <p>We planned to use the generic inverse variance technique to appropriately analyse cluster‐RCTs, taking into account intraclass correlation coefficients to adjust for cluster effects. </p> </section> </section> <section id="CD011006-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>At some degree of loss to follow‐up, data must lose credibility (<a href="./references#CD011006-bbs2-0231" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El-SayehH , et al. Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin2009;33(7):254-7.">Xia 2009</a>). For any particular outcome, if more than 50% of data were unaccounted for, we did not reproduce these data or use them in analyses. However, if more than 50% of those in one arm of a trial were lost, but the total loss was less than 50%, we planned to mark such data with (*) to indicate that such a result may be prone to bias. When dichotomous or continuous outcomes were not reported, we asked trial authors to supply the data. </p> <p>We calculated dichotomous data on a strict ITT basis: dropouts were always included in this analysis. Where participants had been excluded from the trial before the endpoint, we assumed that they experienced a negative outcome by the end of the trial. For continuous variables, we applied a loose ITT analysis, whereby all the participants with at least one postbaseline measurement were represented by their last observation carried forward (LOCF), with due consideration of potential biases, including number and timings of dropouts in each arm. </p> <p>When relevant outcomes were not reported, we asked trial authors to supply the data. In the absence of data from authors, we only employed validated statistical methods to impute missing outcomes, with due consideration of the possible bias of these procedures, in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>) and with <a href="http://www.missingdata.org.uk" target="_blank">www.missingdata.org.uk</a>. When SDs were not reported, we asked authors to supply the data. When only the SE or t‐statistics or P values were reported, we calculated SDs according to <a href="./references#CD011006-bbs2-0105" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200.">Altman 1996</a>. In the absence of data from the authors, we substituted SDs with those reported in other studies in the review (<a href="./references#CD011006-bbs2-0138" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7-10.">Furukawa 2006</a>). </p> </section> <section id="CD011006-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We investigated heterogeneity between studies using the I<sup>2</sup> statistic (<a href="./references#CD011006-bbs2-0149" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>; <a href="./references#CD011006-bbs2-0152" title="IoannidisJP . Interpretation of tests of heterogeneity and bias in meta-analysis. Journal of Evaluation in Clinical Practice2008;14(5):951-7.">Ioannidis 2008</a>) and by visual inspection of the forest plots. We considered an I<sup>2</sup> value of 50% or greater to indicate substantial heterogeneity. </p> </section> <section id="CD011006-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use the tests for funnel plot asymmetry to investigate small‐study effects (<a href="./references#CD011006-bbs2-0213" title="SterneJA , GavaghanD , EggerM . Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology2000;53(11):1119-29.">Sterne 2000</a>), if there were at least 10 studies included in the meta‐analysis, with cautious interpretation of the results by visual inspection (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). Since we were unable to conduct any analysis including at least 10 studies we did not use a funnel plot. When there was evidence of small‐study effects, we aimed to investigate possible reasons for funnel plot asymmetry, including publication bias. </p> </section> <section id="CD011006-sec-0046"> <h4 class="title">Data synthesis</h4> <p>If a sufficient number of clinically similar studies was available, we pooled their results in meta‐analyses. </p> <p>For continuous data, we pooled the mean differences (MDs) with a 95% CIs between the treatment arms at the time point of interest, if all studies measured the outcome using the same rating scale; otherwise we pooled standardised mean differences (SMDs). For dichotomous data, we pooled the RR with a 95% CI. For the analysis of dichotomous data, we employed the Mantel‐Haenszel methods. For statistically significant results, we calculated the number needed to treat for an additional beneficial outcome (NNTB). We included studies that compared more than two intervention groups of the same drug (i.e. different dosages) in meta‐analysis by combining arms of the studies into a single group, for the intervention and for the control group respectively, as recommended in Section 23.3.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). If data were binary, we simply added and combined them into one group or divided the comparison arm into two (or more) as appropriate. If data were continuous, we combined the data following the formula in Chapter 6, Section 6.5.2.10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). We included studies that compared two or more antidepressants with placebo as independent comparisons, splitting the 'shared' group (placebo) into two or more groups with smaller sample size (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). </p> <p>We chose a random‐effects model as heterogeneity was expected (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). We only considered direct comparisons for the meta‐analysis. </p> </section> <section id="CD011006-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We aimed to perform the following subgroup analyses for the primary outcome:</p> <p> <ul id="CD011006-list-0008"> <li> <p>psychiatric diagnosis, separating major depressive disorder, and pooling data from studies including only participants with adjustment disorder, dysthymic disorder, depressive symptoms; </p> </li> <li> <p>previous history of depressive conditions;</p> </li> <li> <p>antidepressant class, in particular separating SSRIs, TCAs and other antidepressants;</p> </li> <li> <p>cancer site, separating breast cancer and other sites;</p> </li> <li> <p>cancer stage, separating early stages (stage 0 and I) and late stages (stage II, III and IV); </p> </li> <li> <p>gender.</p> </li> </ul> </p> <p>We interpreted subgroup analyses with caution, as multiple analyses can lead to false‐positive conclusions (<a href="./references#CD011006-bbs2-0181" title="OxmanAD , GuyattGH . A consumer's guide to subgroup analyses. Annals of Internal Medicine1992;116(1):78-84.">Oxman 1992</a>). </p> </section> <section id="CD011006-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We aimed to perform the following sensitivity analyses for the primary outcome:</p> <p> <ul id="CD011006-list-0009"> <li> <p>excluding studies in which the randomisation process was not clearly reported;</p> </li> <li> <p>excluding studies with unclear concealment of random allocation;</p> </li> <li> <p>excluding studies that did not employ adequate blinding of participants, healthcare providers and outcome assessors; </p> </li> <li> <p>excluding studies that did not employ depressive symptoms as their primary outcome;</p> </li> <li> <p>excluding studies with imputed data.</p> </li> </ul> </p> </section> <section id="CD011006-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared three summary of findings tables summarising the key findings of the systematic review in line with the standard methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). </p> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach and using the GRADEpro Guideline Development Tool (<a href="./references#CD011006-bbs2-0142" title="GRADEpro GDT. Version accessed 1 August 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). This is a web‐based tool for summarising and evaluating the certainty of evidence from scientific data, including systematic reviews and meta‐analyses, which takes into account issues related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and external validity such as directness of results (<a href="./references#CD011006-bbs2-0201" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. training.cochrane.org/handbook/archive/v6. [DOI: 10.1002/9781119536604.ch14]">Schunemann 2019</a>). The GRADE approach categorises the certainty in a body of evidence as ‘high’, ‘moderate’, ‘low’ or ‘very low’ by outcome. This is a result of judgement, but the judgement process operates within a transparent structure. We downgraded the evidence from 'high' certainty by one level for serious (or by two for very serious) concerns for each study limitation. </p> <p>These findings include:</p> <p> <ul id="CD011006-list-0010"> <li> <p>antidepressants compared to placebo for depressive symptoms in people with cancer:</p> <ul id="CD011006-list-0011"> <li> <p>efficacy as a continuous outcome;</p> </li> <li> <p>efficacy as a dichotomous outcome;</p> </li> <li> <p>dropouts due to any cause (acceptability);</p> </li> </ul> </li> <li> <p>antidepressants compared to other antidepressants for depressive symptoms in people with cancer: </p> <ul id="CD011006-list-0012"> <li> <p>efficacy as a continuous outcome;</p> </li> <li> <p>efficacy as a dichotomous outcome;</p> </li> <li> <p>dropouts due to any cause (acceptability).</p> </li> </ul> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011006-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011006-sec-0050"></div> <section id="CD011006-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD011006-sec-0052"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD011006-fig-0001">Figure 1</a> for an illustration of the process of study selection. The search of the electronic databases retrieved 5712 references. We added 47 further references from the handsearching of articles' references and the websites of drug‐approving agencies and pharmaceutical companies. After eliminating the duplicates, we identified 4567 references for screening. Two review authors (GV, BC) independently checked 100% of the titles, with a 'good' degree of agreement according to the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>) (simple kappa statistic 0.81). The two review authors discussed the abstracts for which there was inconsistency between them and achieved complete agreement. One review author (GO) checked the remaining abstracts. The two review authors examined the full text of all 100 records identified after the abstract check in detail. Fourteen studies fulfilled the criteria for eligibility and were included in the review (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). Ten studies contributed to the meta‐analysis for the primary outcome (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). Three studies contributed only to the meta‐analysis for secondary outcomes (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>), and <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a> did not provide useful data for the meta‐analysis. </p> <div class="figure" id="CD011006-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram." data-id="CD011006-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> </div> </section> <section id="CD011006-sec-0053"> <h4 class="title">Included studies</h4> <p>We included 14 studies: 12 published studies (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>), and two unpublished studies (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>). The studies included 1364 participants. A detailed description of each study is reported in the <a href="./references#CD011006-sec-0138" title="">Characteristics of included studies</a> table. </p> <section id="CD011006-sec-0054"> <h5 class="title">Design and interventions</h5> <p>All included studies were randomised and double‐blind. The participants were followed up for one week in one study (<a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>), four weeks in two studies (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>, <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>), five weeks in one study (<a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>), six weeks in four studies (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>), eight weeks in two studies (<a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>), 12 weeks in two studies (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>), 24 weeks in one study (<a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>), and a mean of 15 weeks in one study (range between four and 24 weeks) (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>). Ten studies had two comparison arms (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). Eight of these explored the efficacy of an antidepressant versus placebo (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). Six of these studies used an SSRI (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>), and two used the tetracyclic antidepressant mianserin (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). Two studies compared two antidepressants with a two‐arm, head‐to‐head study design (<a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>: paroxetine versus amitriptyline; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>: fluoxetine versus desipramine). Three studies used a three‐arm design, comparing paroxetine versus desipramine versus placebo (<a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>), mirtazapine versus imipramine versus control (no placebo) (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>), and esketamine versus racemic ketamine versus placebo (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>). In the latter two cases, only the comparison between mirtazapine and imipramine (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>) and esketamine and placebo (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>) were included in the meta‐analysis. One study used a four‐arm design and compared high‐dose esketamine versus low‐dose esketamine versus racemic ketamine versus placebo (<a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). For this study, we only included the comparison between high‐dose esketamine and placebo in the meta‐analysis. In total, 10 studies compared an antidepressant against placebo and four studies compared two antidepressants with a head‐to‐head design (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>). Among these, three studies compared a TCA and an SSRI (<a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>), while one study compared mirtazapine and TCAs (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>). </p> </section> <section id="CD011006-sec-0055"> <h5 class="title">Sample sizes</h5> <p>The mean number of participants per study was about 97, with a minimum sample size of 24 in <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a> and a maximum of 209 in <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>. Only five studies had more than 100 participants (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). </p> </section> <section id="CD011006-sec-0056"> <h5 class="title">Setting</h5> <p>Four studies enroled only outpatients (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). Two studies enroled only inpatients (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). Two studies enroled both inpatients and outpatients (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>). The remaining six studies did not report the setting clearly (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>). </p> </section> <section id="CD011006-sec-0057"> <h5 class="title">Participants</h5> <p>Four studies excluded people aged over 65 years (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>), and one study excluded people aged over 60 years (<a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>), while no studies included only elderly participants. </p> <p>The population of participants was heterogeneous in terms of diagnosis of depression. One study enroled only participants with a diagnosis of major depression based on the <i>Diagnostic and Statistical Manual of Mental Disorders, Third Edition</i> (<i>DSM‐III</i>) (<a href="./references#CD011006-bbs2-0109" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edition. Washington (DC): American Psychiatric Association, 1980.">APA 1980</a>) in association with a score greater than 16 on the 21‐item HAM‐D (<a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). One study enroled participants with a diagnosis of major depression according to DSM‐IV, to Endicott criteria (<a href="./references#CD011006-bbs2-0111" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington (DC): American Psychiatric Association, 1994.">APA 1994</a>), and with a score higher than 14 on the HAM‐D‐17 (<a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>). One study enroled participants with major depression according to ICD‐10 criteria (<a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>). Three studies enroled both people with a diagnosis of major depression and people with adjustment disorders based on DSM‐III‐R (<a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>), on DSM‐III‐R in association with a score greater than 14 on the first 17 items of the 21‐item HAM‐D(<a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>), or on DSM‐III‐R in association with a score greater than 13 on the HADS (<a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>). However, only people with major depression took part in <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>. Three studies enroled people with depressive symptoms, but without a formal diagnosis of depression according to a cut‐off score on standardised rating scales, Two‐Question Screening Survey (TQSS) greater than 2 (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>) and HADS greater than 11 (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>). <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a> used alternative criteria for defining depression (quote: "diagnosis of depression according to the criteria proposed by Stewart [<a href="./references#CD011006-bbs2-0215" title="StewartMA , DrakeF , WinokurG . Depression among medically ill patients. Diseases of the Nervous System1965;26:479-85.">Stewart 1965</a>] for medically ill patients, with slight additional inclusion criteria suggested by Kathol and Petty [<a href="./references#CD011006-bbs2-0156" title="KatholRG , PettyF . Relationship of depression to medical illness. A critical review. Journal of Affective Disorders1981;3:111-21.">Kathol 1981</a>] […]") in association with a cut‐off score on standardised rating scales, Zung Self‐Rating Depression Scale (ZSRDS) greater than 41; HAM‐D‐17 greater than 16. Two studies included individuals with 'mild to moderate depression' as measured with the HAM‐D‐17 rating scale (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). One study included people 'with major depression and/or anxiety disorder' diagnosed by an expert psychiatrist (<a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>). In these individuals "the severity of depression was evaluated via the Hospital Anxiety and Depression Scale (HADS) questionnaire." Finally, <a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a> recruited a mix of individuals with a diagnosis of major depressive disorder, adjustment disorder, anxiety disorders such as generalised anxiety disorder and panic disorder (or a combination of these) according to the DSM‐IV criteria. This study was excluded from the previous update; however, we re‐evaluated this and included it in the current update since the severity of the depressive symptoms as measured by the HADS at baseline was consistent with moderate depression (mean score at HADS scale 22.8). </p> <p>With regards to the cancer type and stage, four studies had mixed populations (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>), but the majority of participants had a diagnosis of breast cancer. In <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>, the population was quite equally distributed between breast, thoracic, genitourinary and other types of cancer. Five studies included only women with breast cancer (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). One study included only people with head and neck cancer (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>), while <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a> included only individuals with haematological cancer, <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a> included only people with cervical carcinoma and <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a> included only people with lung or gastrointestinal cancer. In three studies, the cancer stage was not clearly reported (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>). Three studies included only people with early stages ("localised" or "early locally advanced" disease) (<a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>), while all other studies also recruited people with late‐stage disease (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>). One study included only people with late locally advanced or metastasised disease (<a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>). </p> </section> <section id="CD011006-sec-0058"> <h5 class="title">Outcomes</h5> <p>For efficacy outcomes, most included studies provided continuous data such as mean score or mean change on standardised rating scales, including those considered reliable for the aims of this review, such as HAM‐D (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>), MADRS (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>), or other scales (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>). One study provided only dichotomous data (<a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>), defining "responders" as those who achieved a certain improvement in the rating scale score. This study provided these data only for the six‐month assessment and thus could not be included in the meta‐analysis. </p> <p>For secondary outcomes, most studies provided complete data on total dropouts, due to inefficacy and adverse effects. Three studies provided only partial data on dropouts (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>). Very few studies reported data on other secondary outcomes, such as social adjustment (<a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>) and quality of life (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>). </p> <p>We included 773 people in the efficacy analysis on a continuous outcome between six and 12 weeks (primary outcome) and 886 on a dichotomous outcome; 175 in the analysis of social adjustment, 305 in the quality of life analysis and 1159 in the analysis of dropouts. </p> </section> </section> <section id="CD011006-sec-0059"> <h4 class="title">Excluded studies</h4> <p>Of the 100 articles selected for a full‐text evaluation, we excluded 80, which did not meet one or more inclusion criteria (mostly a wrong diagnostic status), while two are awaiting classification and four were ongoing studies (<a href="#CD011006-fig-0001">Figure 1</a>). </p> <p>In particular, two studies did not enrol participants with cancer, while in 41 studies participants were not depressed when enroled or the studies enroled a population with mixed psychiatric symptoms. Eleven studies were not randomised, one was a review of other studies, eight studies compared placebo with a drug that was not approved for the treatment of depression (psylocybin, methylphenidate). For 11 studies, the comparison group was not reliable because there was no placebo or active comparator. For seven studies, for which there was only the abstract or protocol available, we contacted the authors who informed us that these studies had been withdrawn or changed in their design. Details are reported in <a href="./references#CD011006-sec-0139" title="">Characteristics of excluded studies</a> table. </p> <section id="CD011006-sec-0060"> <h5 class="title">Studies awaiting classification</h5> <p>Two studies are awaiting classification (<a href="./references#CD011006-bbs2-0095" title="N0405078066. Randomised double-blind placebo controlled trial of venlafaxine in recently diagnosed lung cancer patients: effects on symptom profiles after 12 weeks. controlled-trials.com2003. [N0405078066]">N0405078066</a>; <a href="./references#CD011006-bbs2-0096" title="UMIN000008768. A randomized comparative study of efficacy and safety between mirtazapine and duloxetine hydrochloride in patients with cancer. UMIN Clinical Trials Registry2012. [UMIN000008768]">UMIN000008768</a>) (see <a href="./references#CD011006-sec-0140" title="">Characteristics of studies awaiting classification</a> table). We contacted the study authors, but received no reply. </p> </section> <section id="CD011006-sec-0061"> <h5 class="title">Ongoing studies</h5> <p>Four studies are ongoing (<a href="./references#CD011006-bbs2-0097" title="IRCT20220406054440N1. Comparison of the effectiveness of mirtazapine and citalopram on general health and quality of life in patients with major depression and breast cancer in the oncology ward. en.irct.ir/trial/63231 (first received 10 May 2022). ">IRCT20210425051075N1</a>; <a href="./references#CD011006-bbs2-0098" title="NCT04303325. Effect of esketamine on postoperative depression, gut microbiota, Bispectral Index data of depression patients undergoing breast cancer operation (ESPOD-BI) (ESPOD-BI). clinicaltrials.gov/ct2/show/record/NCT04303325 (first received 11 March 2020). [CLINICALTRIALS.GOV: NCT04303325]">NCT04303325</a>; <a href="./references#CD011006-bbs2-0099" title="NCT04763135. Mirtazapine in cancer-related poly-symptomatology (MIR-P). clinicaltrials.gov/ct2/show/record/NCT04763135 (first received 21 February 2021). [CLINICALTRIALS.GOV: NCT04763135]">NCT04763135</a>; <a href="./references#CD011006-bbs2-0100" title="NCT04818099. Vortioxetine in the treatment of depression associated with head and neck cancers undergoing radiotherapy. clinicaltrials.gov/ct2/show/record/NCT04818099 (first received 26 March 2021). [CLINICALTRIALS.GOV: NCT04818099]">NCT04818099</a>) (see <a href="./references#CD011006-sec-0141" title="">Characteristics of ongoing studies</a> table). </p> </section> </section> </section> <section id="CD011006-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>We performed ROB 2 assessment for three outcomes:</p> <p> <ul id="CD011006-list-0013"> <li> <p>efficacy measured as a continuous outcome at six to 12 weeks;</p> </li> <li> <p>efficacy measured as a dichotomous outcome at six to 12 weeks;</p> </li> <li> <p>acceptability.</p> </li> </ul> </p> <p>For the main outcome (efficacy at six to 12 weeks, continuous data), no studies had an overall low risk of bias according to the RoB 2 tool algorithm (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>), and six studies (60%) had an overall high risk of bias (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). The RoB 2 assessment of the secondary outcome 'efficacy at six to 12 weeks', dichotomous data was substantially similar to the assessment of the main outcome, while for the outcome 'acceptability' we found the overall quality of the studies was better, with three studies with an overall low risk of bias (<a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). No studies had a high overall risk of bias for this outcome. </p> <p>We found the overall methodological quality of the included trials to be low.</p> </section> <section id="CD011006-sec-0063"> <h3 class="title" id="CD011006-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD011006-tbl-0001"><b>Summary of findings 1</b> Antidepressants compared to placebo for people with cancer and depression</a>; <a href="./full#CD011006-tbl-0002"><b>Summary of findings 2</b> Selective serotonin reuptake inhibitors (SSRIs) compared to tricyclic antidepressants (TCAs) for people with cancer and depression</a>; <a href="./full#CD011006-tbl-0003"><b>Summary of findings 3</b> Mirtazapine compared to tricyclic antidepressants (TCA) for people with cancer and depression</a> </p> <section id="CD011006-sec-0064"> <h4 class="title">Primary outcome</h4> <section id="CD011006-sec-0065"> <h5 class="title">1. Efficacy at six to 12 weeks (continuous outcome)</h5> <section id="CD011006-sec-0066"> <h6 class="title">1.1 Antidepressants versus placebo</h6> <p>We found a potential beneficial effect of antidepressants as a class versus placebo in efficacy at six to 12 weeks (SMD −0.52, 95% CI −0.92 to −0.12; 7 studies, 511 participants; very low‐certainty evidence; <a href="./references#CD011006-fig-0004" title="">Analysis 1.1</a>; <a href="#CD011006-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD011006-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.1 Antidepressants versus placebo." data-id="CD011006-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.1 Antidepressants versus placebo. </p> </div> </div> </div> </section> <section id="CD011006-sec-0067"> <h6 class="title">1.2 Antidepressants versus antidepressants</h6> <p>We found no difference between SSRIs and TCAs as classes in efficacy at six to 12 weeks (SMD −0.08, 95% CI −0.34 to 0.18; 3 studies, 237 participants; very low‐certainty evidence; <a href="./references#CD011006-fig-0005" title="">Analysis 1.2</a>; <a href="#CD011006-fig-0003">Figure 3</a>). There was no difference between mirtazapine and TCAs (MD −4.80, 95% CI −9.70 to 0.10; 1 study, 25 participants; <a href="./references#CD011006-fig-0006" title="">Analysis 1.3</a>). </p> <div class="figure" id="CD011006-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.2 Antidepressants versus antidepressants." data-id="CD011006-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.2 Antidepressants versus antidepressants. </p> </div> </div> </div> </section> </section> </section> <section id="CD011006-sec-0068"> <h4 class="title">Secondary outcomes</h4> <section id="CD011006-sec-0069"> <h5 class="title">2 Efficacy at one to four weeks (continuous outcome)</h5> <section id="CD011006-sec-0070"> <h6 class="title">2.1 Antidepressants versus placebo</h6> <p>We found a potential beneficial effect of antidepressants as a class versus placebo in efficacy at one to four weeks (SMD −0.48, 95% CI −0.87 to −0.10; 8 studies, 764 participants; <a href="./references#CD011006-fig-0007" title="">Analysis 2.1</a>). </p> <p>For antidepressants versus other antidepressants (mirtazapine versus imipramine), there was no difference between groups in efficacy at one to four weeks (MD −5.00, 95% CI −10.63 to 0.63; 1 study, 32 participants; <a href="./references#CD011006-fig-0008" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD011006-sec-0071"> <h5 class="title">3 Efficacy at six to 12 weeks (dichotomous outcome)</h5> <section id="CD011006-sec-0072"> <h6 class="title">3.1 Antidepressants versus placebo</h6> <p>We found a potential beneficial effect of antidepressants as a class versus placebo in terms of response rate at six to 12 weeks (RR 0.74, 95% CI 0.57 to 0.96; 7 studies, 662 participants; very low‐certainty evidence; <a href="./references#CD011006-fig-0009" title="">Analysis 3.1</a>). </p> </section> <section id="CD011006-sec-0073"> <h6 class="title">3.2 Antidepressants versus antidepressants</h6> <p>We found no difference between SSRIs and TCAs as classes in efficacy at six to 12 weeks (RR 1.10, 95% CI 0.78 to 1.53; 2 studies, 199 participants; very low‐certainty evidence). We found no difference between mirtazapine and TCAs in efficacy at six to 12 weeks (RR 0.81, 95% CI 0.60 to 1.09; 1 study, 33 participants; very low‐certainty evidence; <a href="./references#CD011006-fig-0010" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD011006-sec-0074"> <h5 class="title">4 Social adjustment at six to 12 weeks</h5> <section id="CD011006-sec-0075"> <h6 class="title">4.1 Antidepressants versus antidepressants</h6> <p>We found no studies comparing antidepressants versus placebo reporting social adjustment at six to 12 weeks. </p> <p>There was no difference between paroxetine and amitriptyline in social adjustment at six to 12 weeks (MD 0.10, 95% CI −0.38 to 0.58; 1 study, 175 participants; negative values favour paroxetine on the MADRS rating scale; <a href="./references#CD011006-fig-0012" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD011006-sec-0076"> <h5 class="title">5 Health‐related quality of life at six to 12 weeks</h5> <section id="CD011006-sec-0077"> <h6 class="title">5.1 Antidepressants versus placebo</h6> <p>We found no difference between antidepressants as a class and placebo in quality of life at six to 12 weeks (SMD 0.05, 95% CI −0.27 to 0.37; 2 studies, 152 participants; <a href="./references#CD011006-fig-0013" title="">Analysis 5.1</a>). </p> </section> <section id="CD011006-sec-0078"> <h6 class="title">5.2 Antidepressants versus antidepressants</h6> <p>There was no difference between paroxetine and amitriptyline in quality of life at six to 12 weeks (MD 6.50, 95% CI 0.21 to 12.79; 1 study, 153 participants; negative values favour paroxetine on the MADRS rating scale; <a href="./references#CD011006-fig-0014" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD011006-sec-0079"> <h5 class="title">6 Dropouts due to any cause (acceptability)</h5> <section id="CD011006-sec-0080"> <h6 class="title">6.1 Antidepressants versus placebo</h6> <p>We found no difference between antidepressants as a class and placebo in dropouts due to any cause (RR 0.85, 95% CI 0.52 to 1.38; 9 studies, 889 participants; very low‐certainty evidence; <a href="./references#CD011006-fig-0015" title="">Analysis 6.1</a>). </p> </section> <section id="CD011006-sec-0081"> <h6 class="title">6.2 Antidepressants versus antidepressants</h6> <p>We found no difference between SSRIs versus TCAs as classes in dropouts due to any cause (RR 0.83, 95% CI 0.53 to 1.30; 3 studies, 237 participants; very low‐certainty evidence; <a href="./references#CD011006-fig-0016" title="">Analysis 6.2</a>). We found no difference between mirtazapine and TCAs as classes in dropouts due to any cause (RR 0.65, 95% CI 0.20 to 2.15; 1 RCT, 33 participants; <a href="./references#CD011006-fig-0016" title="">Analysis 6.2</a>). </p> </section> </section> <section id="CD011006-sec-0082"> <h5 class="title">7 Dropouts due to inefficacy</h5> <section id="CD011006-sec-0083"> <h6 class="title">7.1 Antidepressants versus placebo</h6> <p>We found no difference between antidepressants as a class and placebo in dropouts due to inefficiency (RR 0.41, 95% CI 0.13 to 1.32; 6 studies, 455 participants; <a href="./references#CD011006-fig-0018" title="">Analysis 7.1</a>). </p> </section> <section id="CD011006-sec-0084"> <h6 class="title">7.2 Antidepressants versus antidepressants</h6> <p>We found no difference between SSRIs and TCAs as classes in dropouts due to inefficiency (RR 0.85, 95% CI 0.14 to 5.06; 3 studies, 237 participants; <a href="./references#CD011006-fig-0019" title="">Analysis 7.2</a>). </p> </section> </section> <section id="CD011006-sec-0085"> <h5 class="title">8 Dropouts due to adverse effects (tolerability)</h5> <section id="CD011006-sec-0086"> <h6 class="title">8.1 Antidepressants versus placebo</h6> <p>We found no difference between antidepressants as a class and placebo in dropouts due to adverse effects (RR 1.19, 95% CI 0.54 to 2.62; 9 studies, 889 participants; <a href="./references#CD011006-fig-0020" title="">Analysis 8.1</a>). Among the nine studies included in the analysis, two studies did not contribute to the analyses since there were no events reported in both intervention groups (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). </p> </section> <section id="CD011006-sec-0087"> <h6 class="title">8.2 Antidepressants versus antidepressants</h6> <p>We found no difference between SSRIs and TCAs as classes in dropouts due to adverse effects (RR 1.04, 95% CI 0.55 to 1.99; 3 studies, 237 participants; <a href="./references#CD011006-fig-0021" title="">Analysis 8.2</a>). </p> </section> </section> </section> <section id="CD011006-sec-0088"> <h4 class="title">Subgroup analyses</h4> <section id="CD011006-sec-0089"> <h5 class="title">Psychiatric diagnosis</h5> <p>Results from this subgroup analysis found no differences in the subgroups of people with major depressive disorder versus people with adjustment disorder, dysthymic disorder or depressive symptoms. This is true for both the 'antidepressant‐placebo' and the 'head‐to‐head' comparisons (<a href="./references#CD011006-fig-0022" title="">Analysis 9.1</a>; <a href="./references#CD011006-fig-0023" title="">Analysis 9.2</a>). However, for the comparison of antidepressants versus placebo, the subgroup analysis seems to confirm the trend of the primary outcome, suggesting a positive effect of antidepressants rather than placebo in both populations (participants with major depressive disorder: RR −0.53, 95% CI −1.38 to 0.32; 3 studies, 291 participants; participants with adjustment disorder, dysthymic disorder and depressive symptoms: RR −0.28, 95% CI −0.67 to 0.10; 2 studies, 107 participants; <a href="./references#CD011006-fig-0022" title="">Analysis 9.1</a>). </p> </section> <section id="CD011006-sec-0090"> <h5 class="title">Previous history of depressive conditions</h5> <p>We did not perform this analysis since the data provided were not sufficient to measure the primary outcome in this subgroup of participants. </p> </section> <section id="CD011006-sec-0091"> <h5 class="title">Antidepressant class</h5> <p>In the main analysis, we pooled data separating the SSRIs, TCAs and other antidepressants classes of antidepressants. Considering the 'antidepressant‐placebo' comparison, we found a potential beneficial effect for SSRIs versus placebo (SMD −0.40, 95% CI −0.79 to −0.01; 5 studies, 238 participants). There was no difference to support the efficacy of TCAs versus placebo (MD 0.04, 95% CI −0.95 to 1.04; 1 study, 17 participants). We included in the 'other antidepressants' class two atypical antidepressants with different mechanisms of action: esketamine and mianserin. There were no differences between this drug class and placebo, although there was a trend indicating a potential beneficial effect for both treatments (SMD −1.01, 95% CI −2.44 to 0.41; 2 studies, 256 participants). The 'head‐to‐head' comparison found no differences between SSRIs and TCAs as classes (SMD −0.08, 95% CI −0.34 to 0.18; 3 studies, 237 participants; <a href="./references#CD011006-fig-0005" title="">Analysis 1.2</a>) or between mirtazapine and TCAs (SMD −4.80, 85% CI −9.70 to 0.10; 1 study, 25 participants; <a href="./references#CD011006-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD011006-sec-0092"> <h5 class="title">Cancer site</h5> <p>Results from this subgroup analysis did not change the main findings for the primary outcome. There was no effect when pooling studies that enroled only women with breast cancer (<a href="./references#CD011006-fig-0025" title="">Analysis 10.1</a>; <a href="./references#CD011006-fig-0026" title="">Analysis 10.2</a>). It was technically feasible to separate these two subgroups; however, the 'other sites' subgroup could not be considered a reliable comparison with the 'breast cancer' subgroup because, even if these studies enroled people with different types of cancer, the vast majority of them actually had breast cancer. </p> </section> <section id="CD011006-sec-0093"> <h5 class="title">Cancer stage</h5> <p>Results from this subgroup analysis did not change the main findings for the primary outcome (<a href="./references#CD011006-fig-0027" title="">Analysis 11.1</a>; <a href="./references#CD011006-fig-0028" title="">Analysis 11.2</a>). Two studies amongst those comparing antidepressants versus placebo enroled only people with late‐stage disease (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>); however, <a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a> did not provide data for the primary outcome (efficacy at six to 12 weeks) and was not included in the analysis. Other studies had a mixed population in terms of cancer stage, except for <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>, which enroled only people with stage 0 (carcinoma in situ, early form). Considering the 'head‐to‐head' comparison, only one study enroled people with early‐stage disease, showing no differences between SSRIs and TCAs as classes (MD 0.69, 95% CI −1.61 to 2.99; 1 trial, 38 participants), while other studies had a mixed population (<a href="./references#CD011006-bbs2-0005" title="HollandJC , RomanoSJ , HeiligensteinJH , TepnerRG , WilsonMG . A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology1998;7:291-300. ">Holland 1998</a>). </p> </section> <section id="CD011006-sec-0094"> <h5 class="title">Gender</h5> <p>This analysis is encompassed in the 'cancer site' analysis, because the 'female participant' subgroup matched with the 'breast cancer' subgroup (see <a href="./references#CD011006-fig-0025" title="">Analysis 10.1</a>). A subgroup analysis for men only was not feasible, since other studies enroled both male and female participants. </p> </section> </section> <section id="CD011006-sec-0095"> <h4 class="title">Sensitivity analyses</h4> <section id="CD011006-sec-0096"> <h5 class="title">Excluding trials in which the randomisation process was not clearly reported</h5> <p>We did not perform this sensitivity analysis because only <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a> reported clear details on random sequence generation and concealment of random allocation. </p> </section> <section id="CD011006-sec-0097"> <h5 class="title">Excluding trials with unclear concealment of random allocation</h5> <p>We did not perform this sensitivity analysis because only <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a> reported clear details on random sequence generation and concealment of random allocation. </p> </section> <section id="CD011006-sec-0098"> <h5 class="title">Excluding trials that did not employ adequate blinding of participants, healthcare providers and outcome assessors </h5> <p>We did not perform this sensitivity analysis because no studies reported clear details on the procedures for ensuring blinding. </p> </section> <section id="CD011006-sec-0099"> <h5 class="title">Excluding trials that did not employ depressive symptoms as their primary outcome</h5> <p>Three studies assessed depressive symptoms as a secondary outcome (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>), with two contributing to the 'antidepressants versus placebo' analysis and <a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a> comparing mirtazapine versus imipramine. Results from this sensitivity analysis did not change the main findings for the primary outcome (<a href="./references#CD011006-fig-0029" title="">Analysis 12.1</a>). </p> </section> <section id="CD011006-sec-0100"> <h5 class="title">Excluding trials with imputed data</h5> <p>Seven studies did not impute missing data, applying a 'per protocol', an 'as treated' or a 'modified Intent‐to‐treat' analysis (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>; <a href="./references#CD011006-bbs2-0011" title="RazaviD , AllilaireJF , SmithM , SalimpourA , VerraM , DesclauxB , et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica1996;94:205-10. ">Razavi 1996</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>). These studies contributed only to the 'antidepressants versus placebo' analysis. After removing studies with imputed data the meta‐analysis showed a small superiority of antidepressants over placebo confirming substantially the main findings of the meta‐analysis (SMD −0.65, 95% CI −1.10 to −0.20; 6 studies, 476 participants; <a href="./references#CD011006-fig-0030" title="">Analysis 13.1</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011006-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011006-sec-0101"></div> <section id="CD011006-sec-0102"> <h3 class="title" id="CD011006-sec-0102">Summary of main results</h3> <p>We included 14 RCTs involving 1364 participants in this review update. The updated electronic search and handsearch for new studies trials (and for new data on studies previously awaiting classification), allowed us to identify four new studies (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). Two studies assessed the efficacy of intravenous injection of esketamine against placebo (normal saline) (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a> assessed the efficacy of sertraline against placebo and <a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a> assessed the efficacy of mirtazapine against imipramine. Three studies contributed to the primary outcome (efficacy as a continuous outcome at six to 12 weeks) (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>; <a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>). </p> <p>The included studies did not report all the outcomes that were prespecified in the original protocol. Ten studies provided continuous data, which contributed to the meta‐analysis for the primary outcome of efficacy as a continuous outcome at six to 12 weeks (<a href="./references#CD011006-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD011006-fig-0005" title="">Analysis 1.2</a>). Only one study did not provide data suitable for any of the meta‐analyses (<a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>). Most studies provided detailed data on dropouts, while for some other secondary outcomes, such as social adjustment and quality of life, very few studies provided data (<a href="./references#CD011006-fig-0012" title="">Analysis 4.1</a>; <a href="./references#CD011006-fig-0013" title="">Analysis 5.1</a>; <a href="./references#CD011006-fig-0014" title="">Analysis 5.2</a>). </p> <p>Overall, we detected a small beneficial effect between antidepressants as a class and placebo in terms of efficacy, in both continuous and dichotomous outcomes. There was no evidence of difference concerning acceptability (dropouts due to any cause), and tolerability (dropouts due to adverse events). For the primary outcome (efficacy as a continuous outcome at six to 12 weeks) we found mianserin, sertraline and esketamine to be effective over placebo. For the primary outcome, the sensitivity analysis excluding studies with imputed data gave similar results. Our study suggested a small benefit of antidepressants versus placebo in the early response phase (one to four weeks), but this analysis was limited by substantial statistical heterogeneity. No studies assessed follow‐up response after more than 12 weeks. In head‐to‐head comparisons, we retrieved data for SSRIs versus TCAs and we added in this update one small study comparing mirtazapine versus imipramine (<a href="./references#CD011006-bbs2-0001" title="CankurtaranES , OzalpE , SoygurH , AkbiyikDI , TurhanL , AlkisN . Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer2008;16(11):1291-8. [DOI: 10.1007/s00520-008-0425-1.]">Cankurtaran 2008</a>). For both head‐to‐head comparisons, we found no difference between the classes of antidepressants. </p> <p>For the secondary outcome 'remission rate at six to 12 weeks', we found a small beneficial effect in the antidepressant‐placebo comparison, in favour of antidepressants, while there was no difference in the head‐to‐head comparisons. Very few studies contributed to the secondary outcomes 'social adjustment' and 'quality of life', and, therefore, no relevant findings emerged. For the secondary outcome 'acceptability', we found only mianserin had lower dropouts due to inefficacy and dropouts due to any cause compared with placebo. In head‐to‐head comparisons, we retrieved data for SSRIs versus TCAs and mirtazapine versus TCAs. There were no differences between these classes in terms of dropout due to inefficacy and tolerability. </p> </section> <section id="CD011006-sec-0103"> <h3 class="title" id="CD011006-sec-0103">Overall completeness and applicability of evidence</h3> <p>Most participants had a diagnosis of breast cancer. There was some degree of heterogeneity in terms of stage of cancer, anticancer treatments and psychiatric diagnosis, including different depressive conditions. The overall number of participants was very low, and this population could hardly reflect the complexity of people with cancer from a 'real world' setting. Furthermore, it is worth noting that there were no studies conducted on older people only, despite this population representing a relevant portion of the oncological population. </p> <p>Most studies enroled a very small number of participants and did not provide data for all the outcomes specified in the protocol. For these reasons, most of the analyses were underpowered and this limits the overall completeness of the evidence. In particular, we chose to consider efficacy as a continuous outcome at six to 12 weeks as the primary outcome, this being, in our opinion, a more reliable outcome for clinical practice. However, we had to exclude some studies from this analysis because they did not report continuous outcomes or they performed the assessment at a different time point. </p> <p>Another important issue was retrieving data from unpublished studies. Even though we found a relatively consistent number of unpublished studies in the online registers, reliable data that we could include in the meta‐analysis were not available. Very few authors replied to our request for information or data and we included only two unpublished studies (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>). Three studies were ongoing and we classified two studies as awaiting classification, as they were eligible according to the protocol or the abstract, but did not provide any data for meta‐analysis. Considering the overall small number of studies included and the uncertainty of the evidence, it is plausible that these studies could have made a relevant difference to our analysis. </p> <p>We chose to consider only the dropout rate due to adverse events as a proxy of the tolerability of treatments because in this particular population the most common adverse effects of antidepressants (e.g. asthenia, sedation, headache, nausea and gastrointestinal problems) are very likely to be caused also by other anticancer therapies, pain syndromes or the direct effects of cancer. We know from previous literature that antidepressants are generally well tolerated by people with medical illnesses (<a href="./references#CD011006-bbs2-0190" title="RaynerL , PriceA , EvansA , ValsrajK , HigginsonIJ , HotopfM . Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007503. [DOI: 10.1002/14651858.CD007503.pub2]">Rayner 2010</a>), even when very complex and advanced (including people with cancer) (<a href="./references#CD011006-bbs2-0191" title="RaynerL , PriceA , EvansA , ValsrajK , HotopfM , HigginsonIJ . Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliative Medicine2011;25(1):36-51.">Rayner 2011a</a>). However, some authors showed possible toxicities of antidepressants in this population (<a href="./references#CD011006-bbs2-0083" title="StocklerMR , O'ConnellR , NowakAK , GoldsteinD , TurnerJ , WilckenNR , et al, Zoloft's Effects on Symptoms and Survival Time Trial Group. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology2007;8(7):603-12. [PMID: 17548243]">Stockler 2007</a>), and the issue of possible cardiac effects of citalopram and escitalopram (<a href="./references#CD011006-bbs2-0177" title="NosèM , BighelliI , CastellazziM , MartinottiG , CarràG , LuciiC , et al: STAR Network Group. Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiology and Psychiatric Sciences2016;25(6):532-40. [DOI: 10.1017/S2045796015000906]">Nosé 2016</a>; <a href="./references#CD011006-bbs2-0198" title="SarganasG , GarbeE , KlimpelA , HeringRC , BronderE , HaverkampW . Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace2014;16(1):101-8. [DOI: 10.1093/europace/eut214]">Sarganas 2014</a>) may be particularly relevant for people with cancer. For this reason, further analysis may be relevant for assessing the occurrence of adverse effects likely linked to antidepressants. It is worth noting that two studies newly included in this update compared the efficacy of intravenous esketamine versus placebo (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0014" title="WangJ , WangY , XuX , PengS , XuF , LiuP . Use of various doses of S-ketamine in treatment of depression and pain in cervical carcinoma patients with mild/moderate depression after laparoscopic total hysterectomy. Medical Science Monitoring2020;26:e922028-1-6. [DOI: 10.12659/MSM.922028]">Wang 2020</a>). These studies could not measure tolerability and acceptability of the treatment since participants received the treatment in a single administration while undergoing surgery, therefore there was no possibility for the individuals to withdraw the assigned treatment. </p> <p>It has been suggested that the efficacy of tamoxifen, a drug broadly used for the prevention and treatment of breast cancer, could be lessened by some antidepressants that act on CYP2D6 inhibitors. Therefore, this would worsen the prognosis of these people over a five‐year period (<a href="./references#CD011006-bbs2-0157" title="KellyCM , JuurlinkDN , GomesT , Duong-HuaM , PritchardKI , AustinPC , et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ2010;340(c693):1-8. [DOI: 10.1136/bmj.c693]">Kelly 2010</a>). The most relevant effect has been shown for paroxetine, however other drugs, such as fluoxetine, bupropion and duloxetine, could theoretically have a similar effect, and should be therefore avoided in this population (<a href="./references#CD011006-bbs2-0107" title="AndradeC . Breast cancer and antidepressant use. Journal of Clinical Psychiatry2012;73(9):e1156-7. [DOI: 10.4088/JCP.12f08054]">Andrade 2012</a>). This possible effect is unlikely to have affected our analysis, since two studies used paroxetine (<a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>; <a href="./references#CD011006-bbs2-0010" title="PezzellaG , Moslinger-GehmayrR , ContuA . Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment2001;70:1-10. ">Pezzella 2001</a>), and only one included participants possibly taking tamoxifen (<a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>), and the follow‐up period was relatively short to appreciate this potentially harmful effect. </p> </section> <section id="CD011006-sec-0104"> <h3 class="title" id="CD011006-sec-0104">Quality of the evidence</h3> <p>The overall methodological quality of the included studies was poor (<a href="#CD011006-fig-0002">Figure 2</a>; <a href="#CD011006-fig-0002">Figure 2</a>). For the primary outcome of efficacy at six to 12 weeks as a continuous outcome only two studies showed an overall low risk of bias (<a href="./references#CD011006-bbs2-0006" title="LiuP , LiP , LiQ , YanH , ShiX , LiuC , et al. Effect of pretreatment of S-ketamine on postoperative depression for breast cancer patients. Journal of Investigative Surgery2021;34(8):883-8. [DOI: 10.1080/08941939.2019.1710626]">Liu 2021</a>; <a href="./references#CD011006-bbs2-0012" title="Tavakoli ArdakaniM , MehrpooyaM , MehdizadehM , BeiraghiN , HajifathaliA , KazemiMH . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplantation2020;55(4):830-2. [DOI: 10.1007/s12185-017-2309-y] [DOI: 10.1038/s41409-019-0623-0]">Tavakoli Ardakani 2019</a>). Most studies had poor methodological quality, as out of the 10 studies that contributed to the primary outcome, five (50%) were at high risk of bias. This was mainly due to four studies having a very high dropout rate and high risk for bias due to missing outcome data. Furthermore, in some cases, the poor quality of the study seemed to reflect the lack of exhaustive reporting rather than clear evidence of bias, especially for the older studies. This is consistent with the finding of general suboptimal reporting of studies in medical journals despite the large number of instruments designed to help transparent reporting, such as the CONSORT Statement (<a href="./references#CD011006-bbs2-0218" title="TurnerL , ShamseerL , AltmanDG , WeeksL , PetersJ , KoberT , et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: MR000030. [DOI: 10.1002/14651858.MR000030.pub2]">Turner 2012</a>). </p> <p>We used GRADEpro GDT to provide outcome‐specific information concerning the overall certainty of the evidence from each included study in the comparison and the magnitude of the effect of the interventions examined. Our overall confidence in the estimate of effect was very low for all main outcomes assessed (i.e. efficacy as a continuous outcome, efficacy as a dichotomous outcome and dropout due to any cause; see <a href="./full#CD011006-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011006-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011006-tbl-0003">summary of findings Table 3</a>). This judgement reflects some issues in the included studies, namely the high risk of bias (due to poor methodological quality and high dropout rates), inconsistency (due to the high degree of heterogeneity between RCTs) and imprecision (due to the low number of participants in each study and wide CIs). In accordance with this, any estimate of effect in this review should be considered very uncertain, and further research is very likely to change the estimate of effect and thus the degree of confidence for its applicability in routine clinical practice. </p> </section> <section id="CD011006-sec-0105"> <h3 class="title" id="CD011006-sec-0105">Potential biases in the review process</h3> <p>There are several possible limitations of this review, and thus the interpretation of results should remain provisional and tentative. </p> <p>Some limitations are intrinsically related to the actual process of retrieving, collecting, selecting and extracting data. In order to reduce the potential bias of this complex process, two review authors independently worked on each of these steps. With regards to the selection of relevant studies, the degree of agreement between the two review authors was evaluated with the calculation of 'simple kappa statistics,' which confirmed the reliability of the selection process (see <a href="#CD011006-sec-0052">Results of the search</a>). It has been highlighted that data extraction performed by two extractors independently is, overall, more reliable than the extraction performed by a single author followed by verification by a second author (<a href="./references#CD011006-bbs2-0120" title="BuscemiN , HartlingL , VandermeerB , TjosvoldL , KlassenTP . Single data extraction generated more errors than double data extraction in systematic reviews. Journal of Clinical Epidemiology2006;59:697-703.">Buscemi 2006</a>). We applied the same process for the risk of bias assessment. Furthermore, we discussed disagreements with a third review author, who also checked the data extracted from studies when the analysis was performed. Another relevant problem concerns the 'systematic' nature of the search. We chose to include only RCTs as they provide the strongest level of evidence available. In this type of review, there is some risk of publication bias, which means that negative studies may have not been published. Some authors of this review are experts in the field, thus it is unlikely that significant studies were overlooked. However, whilst the search was thorough, it is possible that there are still unpublished studies that have not been identified, considering that there are no shared procedures to perform this type of search (<a href="./references#CD011006-bbs2-0125" title="ChanAW . Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ2012;3(344):d8013. [DOI: 10.1136/bmj.d8013]">Chan 2012</a>). The impact of unpublished literature on the results of this review is uncertain; however, it is expected that the analysis of only published literature would lead to an overestimation of the efficacy of a given intervention (<a href="./references#CD011006-bbs2-0217" title="TurnerEH , MatthewsAM , LinardatosE , TellRA , RosenthalR . Selective publication of antidepressants trials and its influence on apparent efficacy. New England Journal of Medicine2008;358:252-60. [DOI: 10.1056/NEJMsa065779]">Turner 2008</a>). Moreover, the search date is November 2022 and there are two studies classified as 'awaiting classification,' the eligibility of which is yet to be determined. At the end of this process, we identified very few studies and the data of interest obtained were relatively limited. </p> <p>It is important to consider that some of the included studies were funded by the pharmaceutical industry, and this may again introduce an overestimation of the efficacy of interventions. </p> <p>To assess efficacy, we gave preference to rating scales administered by clinicians or expert assessors (HAM‐D, MADRS, CGI). Even though they are standardised tools commonly used in studies of antidepressants, they are all potentially prone to observer bias. Three studies used self‐administered questionnaires (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0004" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungS , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [DOI: 10.1200/JCO.2003.08.025]">Fisch 2003</a>; <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a>). We noted some heterogeneity in terms of outcome measurement, and this might represent a limitation in interpreting the effect of interventions. For instance, in <a href="./references#CD011006-fig-0004" title="">Analysis 1.1</a>, <a href="./references#CD011006-fig-0007" title="">Analysis 2.1</a>, <a href="./references#CD011006-fig-0018" title="">Analysis 7.1</a>, and <a href="./references#CD011006-fig-0015" title="">Analysis 6.1</a>, <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a> showed a notably higher beneficial effect of the antidepressant (in this case, mianserin) over placebo compared to other studies, and this affects the final result of the meta‐analyses. In general, the positive effect shown in the mianserin studies had a relevant impact on overall results (<a href="./references#CD011006-bbs2-0002" title="CostaD , MogosI , TomaT . Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica1985;72(Suppl 320):85-92. ">Costa 1985</a>; <a href="./references#CD011006-bbs2-0013" title="vanHeeringenK , ZivkovM . Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry1996;69:440-4. [10.1192/bjp.169.4.440]">Van Heeringen 1996</a>) (<a href="./references#CD011006-fig-0007" title="">Analysis 2.1</a>; <a href="./references#CD011006-fig-0009" title="">Analysis 3.1</a>). Another limitation is the use of non‐specific rating scales, designed for assessing specific psychiatric symptoms and domains, rather than mood disorders in medically ill people. </p> <p>One important limitation of the included studies (and consequently of the present review) was that not all studies reported a continuous outcome for the chosen time points, underpowering the analyses and undermining the possibility of finding differences between comparisons. </p> <p>The studies rarely reported quality of life and social functioning. This possibly limits our interpretation of the efficacy of intervention, which should not be focused only on depression, considering that comorbid depressive symptoms deeply impact the overall burden of disease alongside quality of life and functioning (<a href="./references#CD011006-bbs2-0112" title="ArrietaO , AnguloLP , Núñez-ValenciaC , Dorantes-GallaretaY , MacedoEO , Martínez-LópezD , et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Annals of Surgical Oncology2013;20(6):1941-8.">Arrieta 2013</a>). Some authors also described a relevant impact of comorbid depression on cancer mortality (<a href="./references#CD011006-bbs2-0164" title="Lloyd-WilliamsM , ShielsC , TaylorF , DennisM . Depression – an independent predictor of early death inpatients with advanced cancer. Journal of Affective Disorders2009;113:127-32.">Lloyd‐Williams 2009</a>; <a href="./references#CD011006-bbs2-0186" title="PinquartM , DubersteinPR . Depression and cancer mortality: a meta-analysis. Psychological Medicine2010;40(11):1797-810.">Pinquart 2010</a>; <a href="./references#CD011006-bbs2-0200" title="SatinJR , LindenW , PhillipsMJ . Depression as a predictor of disease progression and mortality in cancer patients. A meta-analysis. Cancer2009;22:5349-61.">Satin 2009</a>). The included studies did not describe this outcome due to relatively short periods of follow‐up. </p> <p>The dropout rate due to any cause is considered a consistent measure for the acceptability of treatment, as it encompasses dropouts due to adverse events and dropouts due to inefficacy and any other cause. However, this is only a proxy measure for this outcome since it comprises very heterogeneous reasons for leaving the study early, a detailed description of which was beyond the aim of this review. </p> <p>For one three‐armed study which compared paroxetine versus desipramine versus placebo (<a href="./references#CD011006-bbs2-0007" title="MusselmanDL , SomersetWI , GuoY , ManatungaAK , PorterM , PennaS , et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Journal of Clinical Psychiatry2006;67(2):288-96. ">Musselman 2006</a>), we chose to split the 'shared' group (in this case the placebo group) into two groups with smaller sample sizes, in order to avoid reporting the same subpopulation of participants in the analysis. These smaller groups contributed to one comparison each (namely paroxetine versus placebo and desipramine versus placebo). In the analysis of dichotomous outcomes, the number of events was also split between the two comparisons. This method, although considered reliable according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> is not the most recommended since it only partially overcomes the unit of analysis error (because the resulting comparisons remain correlated) (<a href="./references#CD011006-bbs2-0150" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA . Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.cochrane-handbook.org.">Higgins 2022</a>). </p> <p>Finally, it is very relevant to note that people with different types and stages of cancer cannot be considered a homogeneous group, considering there are differences in genetic, biological and immunological mechanisms, as well as in physical and psychosocial impairment. Due to the paucity of data, several subgroup analyses that would have investigated these characteristics were not feasible. We interpreted the results from these analyses cautiously, since multiple calculations may risk producing a result that is statistically significant by chance alone. </p> </section> <section id="CD011006-sec-0106"> <h3 class="title" id="CD011006-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p>Analyses from this study draw different conclusions with respect to previous reviews and meta‐analyses. Results from the meta‐analyses by <a href="./references#CD011006-bbs2-0145" title="HartSL , HoytMA , DiefenbachM , AndersonDR , KilbournKM , CraftLL , et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. Journal of the National Cancer Institute2012;104(13):990-1004.">Hart 2012</a> and <a href="./references#CD011006-bbs2-0223" title="WalkerJ , SawhneyA , Holm HansenC , AhmedS , MartinP , SymeonidesS , et al. Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychological Medicine2014;44(5):897-907.">Walker 2014</a> are not comparable to the present study since they enroled only people with elevated depressive symptoms (<a href="./references#CD011006-bbs2-0145" title="HartSL , HoytMA , DiefenbachM , AndersonDR , KilbournKM , CraftLL , et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. Journal of the National Cancer Institute2012;104(13):990-1004.">Hart 2012</a>) and a formal diagnosis of major depression (<a href="./references#CD011006-bbs2-0223" title="WalkerJ , SawhneyA , Holm HansenC , AhmedS , MartinP , SymeonidesS , et al. Treatment of depression in adults with cancer: a systematic review of randomized controlled trials. Psychological Medicine2014;44(5):897-907.">Walker 2014</a>). Conversely, the meta‐analysis by <a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a> included the same studies as our review, with the difference of two (rather small) unpublished studies (<a href="./references#CD011006-bbs2-0003" title="EUCTR2008-002159-25-FR. A randomized, double-blind, placebo-controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer [Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement]. www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25 (first received 24 September 2008). [EUCTR2008-002159-25-FR]">EUCTR2008‐002159‐25‐FR</a>; <a href="./references#CD011006-bbs2-0009" title="NCT00387348. Escitalopram in treating depression in patients with advanced lung or gastrointestinal cancer. clinicaltrials.gov/ct2/show/NCT00387348 (first received 13 October 2006). [NCT00387348]">NCT00387348</a>). In <a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a>, there was a superiority of antidepressants versus placebo in terms of 'therapeutic response' (as a dichotomous outcome) (RR 1.56, 95% CI 1.07 to 2.28; P = 0.021). Their analysis slightly differed from the one performed in the present systematic review, where we found no difference (<a href="./references#CD011006-fig-0009" title="">Analysis 3.1</a>). In contrast with the meta‐analysis by <a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a>, the study carried out by <a href="./references#CD011006-bbs2-0008" title="NavariRM , BrennerMC , WilsonMN . Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment2008;112:197-201. [DOI: 10.1007/s10549-007-9841-z]">Navari 2008</a> was not eligible for our analysis as our focus was the 'acute phase treatment response' (between six and 12 weeks), while this study reported the number of responders at week 24. Other differences referred to different approaches employed in the definition of some ITT populations. Moreover, <a href="./references#CD011006-bbs2-0161" title="LaoutidisZG , MathiakK . Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry2013;13(140):1-21. [DOI: 10.1186/1471-244X-13-140]">Laoutidis 2013</a> performed no analyses of continuous outcomes and, similarly to our analysis, there were no differences between SSRIs and TCAs. Additionally, the review and meta‐analysis by <a href="./references#CD011006-bbs2-0193" title="RibletN , LarsonR , WattsBV , HoltzheimerP . Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. General Hospital Psychiatry2014;36:466-73.">Riblet 2014</a> was difficult to compare with our review, as it included some studies that were excluded from our analysis, in particular one quasi‐randomised study (<a href="./references#CD011006-bbs2-0224" title="WangDS , LiGL , ChenJH , LiuXM . Effects of psychological interventions in cancer patients undergoing radiotherapy. Chinese Journal of Clinical Psychology2011;19(4):561-3.">Wang 2011</a>), and two studies where participants were not depressed at baseline (<a href="./references#CD011006-bbs2-0026" title="Del CarmenL , PlancarteR , De La FuenteJR . Amitriptilin as coanalgesic in cancerous patients [La amitriptilina como coanalgesico en pacientes con cancer]. Salud Mental1990;13(4):1-6. ">Del Carmen 1990</a>; <a href="./references#CD011006-bbs2-0080" title="RoscoeJA , MorrowGR , HickokJT , MustianKM , GriggsJJ , MattesonSE , et al. Effect of paroxetine hydrochloride (Paxilò) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Research and Treatment2005;89(3):243-9. [PMID: 15754122]">Roscoe 2005</a>). </p> <p>In a review published by <a href="./references#CD011006-bbs2-0143" title="GrassiL , NanniMG , RodinG , LiM , CarusoR . The use of antidepressants in oncology: a review and practical tips for oncologists. Annals of Oncology2018;29(1):101-11. [DOI: 10.1093/annonc/mdx526]">Grassi 2018</a>, the authors concluded that the weight of evidence currently available supports the efﬁcacy of antidepressants for more severe major depression in people with cancer and as an adjuvant treatment in cancer‐related symptoms, although the methodological limitations of reported RCTs do not permit definite conclusions. Data also indicate that there should be caution in the use of antidepressants in people with cancer in terms of their safety profile and potential clinically significant interactions with other prescribed medications. This particular study takes into consideration other pharmacological treatments for depression that we did not include in this current review since they are not approved to treat depression (methylphenidate, ketamine, modafinil, psilocybin). </p> <p>The use of antidepressants in people with cancer has been studied in many ways in the scientific literature, focusing not only on treating depressive symptoms or disorders, but also on preventing depression (e.g. <a href="./references#CD011006-bbs2-0045" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [DOI: 10.1200/JCO.2003.04.070]">Morrow 2003</a>, in which antidepressants appeared effective in a population of 549 participants), or treating some cancer‐related symptoms, such as hot flushes, fatigue, insomnia, hyporexia and weigh loss. Most studies enroled people on the basis of medical symptoms and a proper assessment of concomitant depressive conditions was not always performed. These studies were not included in the present review, however they may contribute to broaden the discussion about the clinical suitability of antidepressants in people with cancer, since it has been claimed that a continuum of depressive experiences, ranging from distressing cancer‐related symptoms to proper depressive symptoms or disorders, can be detected in this population (<a href="./references#CD011006-bbs2-0119" title="BrenneE , LogeJH , KaasaS , HeitzerE , KnudsenAK , WestonE . Depressed patients with incurable cancer: which depressive symptoms do they experience?Palliative and Supportive Care2013;11(6):491-500. [DOI: 10.1017/S1478951512000909]">Brenne 2013</a>; <a href="./references#CD011006-bbs2-0170" title="MitchellAJ , ChanM , BhattiH , HaltonM , GrassiL , JohansenC , et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncology2011;12:160-74.">Mitchell 2011</a>; <a href="./references#CD011006-bbs2-0189" title="RaisonCL , MillerAH . Depression in cancer: new developments regarding diagnosis and treatment. Biological Psychiatry2003;54(3):283-94.">Raison 2003</a>), and can be effectively treated with antidepressants (<a href="./references#CD011006-bbs2-0180" title="OstuzziG , BendaL , CostaE , BarbuiC . Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis. Cancer Treatment Reviews2015;41(8):714-24. [10.1016/j.ctrv.2015.06.003]">Ostuzzi 2015a</a>). </p> <p>One systematic review and meta‐analysis by <a href="./references#CD011006-bbs2-0233" title="ZahidJA , GrummedalO , MadsenMT , GögenurI . Prevention of depression in patients with cancer: a systematic review and meta-analysis of randomized controlled trials. Journal of Psychiatric Research2020;120:113-23. [DOI: 10.1016/j.jpsychires.2019.10.009]">Zahid 2020</a> focused on preventing depression in participants with cancer. The work included three groups of intervention (pharmacological, psychological and other type of interventions). Amongst the pharmacological group only three studies contributed to the results of the meta‐analysis and in one of them the pharmacological treatment was melatonin (not included in the current review). In spite of the small number of included studies, the results showed a significant impact of pharmacological treatment in preventing depression in people with cancer (RR 0.34, 95% CI 0.18 to 0.63). However, the authors concluded that "no convincing evidence for any specific intervention is present." </p> <p>Further, another recently published systematic review focused on the pharmacological treatment of depression in older people (aged over 65 years) with cancer (<a href="./references#CD011006-bbs2-0188" title="RabinEE , KimM , MoznyA , CardozaK , BellAC , ZhaiL , et al. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer. Brain Behavior &amp; Immunity – Health2022;21:67. [DOI: 10.1016/j.bbih.2022.100449]">Rabin 2022</a>). Similarly to what we observed, the study authors concluded that there is currently a lack of evidence concerning the management of depression in this specific population, despite the fact that older adults represent most new cancer diagnoses and are specifically vulnerable to develop depressive‐like symptoms. Given its clinical relevance, new research on this topic is critically needed. Some non‐randomised studies were retrieved (<a href="./references#CD011006-bbs2-0017" title="BigliaN , TortaR , RoagnaR , MaggiorottoF , CacciariF , PonzoneR , et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas2005;52(1):78-85. [PMID: 16143229]">Biglia 2005</a>; <a href="./references#CD011006-bbs2-0021" title="CalderaPC , AmodeoL , BorioR , RamondaE , TortaR . Algorithm-based treatment for depression in cancer outpatients: efficacy and tolerability evaluation of newer antidepressants. Psycho-oncology2009;18(Suppl 2):S317. [DOI: 10.1002/pon.1594]">Caldera 2009</a>; <a href="./references#CD011006-bbs2-0030" title="EvansDL , McCartneyCF , HaggertyJJ . Treatment of depression in cancer patients is associated with better life adaptation: a pilot study. Psychosomatic Medicine1988;50:72-6. ">Evans 1988</a>; <a href="./references#CD011006-bbs2-0040" title="KCT0000076. Effects of bupropion and escitalopram for depression in cancer patients. International Clinical Trials Registry Platform2011. [KCT0000076]">KCT0000076</a>; <a href="./references#CD011006-bbs2-0050" title="NCT00234195. Wellbutrin XL, major depressive disorder and breast cancer. clinicaltrials.gov/ct2/show/NCT00234195 (first received 6 October 2005). ">NCT00234195</a>; <a href="./references#CD011006-bbs2-0064" title="NCT01725048. Pilot study to evaluate individualized choice of antidepressants in patients with cancer. clinicaltrials.gov/ct2/show/NCT01725048 (first received 12 November 2012). ">NCT01725048</a>; <a href="./references#CD011006-bbs2-0087" title="TondlovaH , BagteckyJ . Citalopram in the treatment of depression in patients suffering from simultaneous serious somatic disorders. European Neuropsychopharmacology1997;7(2):188. [DOI: 10.1016/S0924-977X(97)88616-6]">Tondlova 1997</a>); however, for most of these only conference procedures or protocols were available. Moreover, results from the remaining studies did not provide a relevant contribution to the discussion, since they were performed on very small numbers of participants (<a href="./references#CD011006-bbs2-0017" title="BigliaN , TortaR , RoagnaR , MaggiorottoF , CacciariF , PonzoneR , et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas2005;52(1):78-85. [PMID: 16143229]">Biglia 2005</a>; <a href="./references#CD011006-bbs2-0030" title="EvansDL , McCartneyCF , HaggertyJJ . Treatment of depression in cancer patients is associated with better life adaptation: a pilot study. Psychosomatic Medicine1988;50:72-6. ">Evans 1988</a>). </p> <p>We retrieved four ongoing studies (<a href="./references#CD011006-bbs2-0098" title="NCT04303325. Effect of esketamine on postoperative depression, gut microbiota, Bispectral Index data of depression patients undergoing breast cancer operation (ESPOD-BI) (ESPOD-BI). clinicaltrials.gov/ct2/show/record/NCT04303325 (first received 11 March 2020). [CLINICALTRIALS.GOV: NCT04303325]">NCT04303325</a>; <a href="./references#CD011006-bbs2-0099" title="NCT04763135. Mirtazapine in cancer-related poly-symptomatology (MIR-P). clinicaltrials.gov/ct2/show/record/NCT04763135 (first received 21 February 2021). [CLINICALTRIALS.GOV: NCT04763135]">NCT04763135</a>; <a href="./references#CD011006-bbs2-0100" title="NCT04818099. Vortioxetine in the treatment of depression associated with head and neck cancers undergoing radiotherapy. clinicaltrials.gov/ct2/show/record/NCT04818099 (first received 26 March 2021). [CLINICALTRIALS.GOV: NCT04818099]">NCT04818099</a>, <a href="./references#CD011006-bbs2-0097" title="IRCT20220406054440N1. Comparison of the effectiveness of mirtazapine and citalopram on general health and quality of life in patients with major depression and breast cancer in the oncology ward. en.irct.ir/trial/63231 (first received 10 May 2022). ">IRCT20210425051075N1</a>), and two studies are awaiting classification (<a href="./references#CD011006-bbs2-0095" title="N0405078066. Randomised double-blind placebo controlled trial of venlafaxine in recently diagnosed lung cancer patients: effects on symptom profiles after 12 weeks. controlled-trials.com2003. [N0405078066]">N0405078066</a>; <a href="./references#CD011006-bbs2-0096" title="UMIN000008768. A randomized comparative study of efficacy and safety between mirtazapine and duloxetine hydrochloride in patients with cancer. UMIN Clinical Trials Registry2012. [UMIN000008768]">UMIN000008768</a>). Data from these studies, even partial or provisional, were not available, thus their possible impact remains unclear. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011006-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram." data-id="CD011006-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.1 Antidepressants versus placebo." data-id="CD011006-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.1 Antidepressants versus placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.2 Antidepressants versus antidepressants." data-id="CD011006-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Depression: efficacy at six to 12 weeks (continuous outcome), outcome: 1.2 Antidepressants versus antidepressants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Depression: efficacy as a continuous outcome at 6–12 weeks, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Depression: efficacy as a continuous outcome at 6–12 weeks, Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Depression: efficacy as a continuous outcome at 6–12 weeks, Outcome 2: SSRIs vs TCAs" data-id="CD011006-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Depression: efficacy as a continuous outcome at 6–12 weeks, Outcome 2: SSRIs vs TCAs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Depression: efficacy as a continuous outcome at 6–12 weeks, Outcome 3: Mirtazapine vs TCA" data-id="CD011006-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Depression: efficacy as a continuous outcome at 6–12 weeks, Outcome 3: Mirtazapine vs TCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Depression: efficacy as a continuous outcome at 1–4 weeks, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Depression: efficacy as a continuous outcome at 1–4 weeks, Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Depression: efficacy as a continuous outcome at 1–4 weeks, Outcome 2: Mirtazapine vs TCA" data-id="CD011006-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Depression: efficacy as a continuous outcome at 1–4 weeks, Outcome 2: Mirtazapine vs TCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Depression: efficacy as a dichotomous outcome at 6–12 weeks, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Depression: efficacy as a dichotomous outcome at 6–12 weeks, Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Depression: efficacy as a dichotomous outcome at 6–12 weeks, Outcome 2: SSRI vs TCA" data-id="CD011006-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Depression: efficacy as a dichotomous outcome at 6–12 weeks, Outcome 2: SSRI vs TCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Depression: efficacy as a dichotomous outcome at 6–12 weeks, Outcome 3: Mirtazapine vs TCA" data-id="CD011006-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Depression: efficacy as a dichotomous outcome at 6–12 weeks, Outcome 3: Mirtazapine vs TCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Social adjustment at 6–12 weeks, Outcome 1: Antidepressants vs antidepressants" data-id="CD011006-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Social adjustment at 6–12 weeks, Outcome 1: Antidepressants vs antidepressants</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Quality of life at 6–12 weeks, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Quality of life at 6–12 weeks, Outcome 1: Antidepressants vs placebo</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Quality of life at 6–12 weeks, Outcome 2: Antidepressants vs antidepressants" data-id="CD011006-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Quality of life at 6–12 weeks, Outcome 2: Antidepressants vs antidepressants</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Dropouts due to any cause (acceptability), Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Dropouts due to any cause (acceptability), Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Dropouts due to any cause (acceptability), Outcome 2: SSRI vs TCA" data-id="CD011006-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Dropouts due to any cause (acceptability), Outcome 2: SSRI vs TCA</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Dropouts due to any cause (acceptability), Outcome 3: Mirtazapine vs TCA" data-id="CD011006-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Dropouts due to any cause (acceptability), Outcome 3: Mirtazapine vs TCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Dropouts due to inefficacy, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Dropouts due to inefficacy, Outcome 1: Antidepressants vs placebo</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Dropouts due to inefficacy, Outcome 2: Antidepressants vs antidepressants" data-id="CD011006-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Dropouts due to inefficacy, Outcome 2: Antidepressants vs antidepressants</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Dropouts due to adverse effects (tolerability), Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Dropouts due to adverse effects (tolerability), Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Dropouts due to adverse effects (tolerability), Outcome 2: Antidepressants vs antidepressants" data-id="CD011006-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Dropouts due to adverse effects (tolerability), Outcome 2: Antidepressants vs antidepressants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: psychiatric diagnosis, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: psychiatric diagnosis, Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: psychiatric diagnosis, Outcome 2: SSRI vs TCA" data-id="CD011006-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: psychiatric diagnosis, Outcome 2: SSRI vs TCA</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: psychiatric diagnosis, Outcome 3: Mirtazapine vs TCA" data-id="CD011006-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: psychiatric diagnosis, Outcome 3: Mirtazapine vs TCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: cancer site, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: cancer site, Outcome 1: Antidepressants vs placebo</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: cancer site, Outcome 2: Antidepressants vs antidepressants" data-id="CD011006-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: cancer site, Outcome 2: Antidepressants vs antidepressants</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Subgroup analysis: cancer stage, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Subgroup analysis: cancer stage, Outcome 1: Antidepressants vs placebo</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Subgroup analysis: cancer stage, Outcome 2: Antidepressants vs antidepressants" data-id="CD011006-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Subgroup analysis: cancer stage, Outcome 2: Antidepressants vs antidepressants</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sensitivity analysis: excluding trials that did not employ depressive symptoms as their primary outcome, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Sensitivity analysis: excluding trials that did not employ depressive symptoms as their primary outcome, Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Sensitivity analysis: excluding trials with imputed data, Outcome 1: Antidepressants vs placebo" data-id="CD011006-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Sensitivity analysis: excluding trials with imputed data, Outcome 1: Antidepressants vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011006-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/urn:x-wiley:14651858:media:CD011006:CD011006-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Sensitivity analysis: excluding trials with imputed data, Outcome 2: Mirtazapine vs TCA" data-id="CD011006-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_t/tCD011006-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Sensitivity analysis: excluding trials with imputed data, Outcome 2: Mirtazapine vs TCA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/media/CDSR/CD011006/image_n/nCD011006-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011006-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antidepressants compared to placebo for people with cancer and depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Antidepressants compared to placebo for people with cancer and depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> adults with cancer and depression<br/><b>Settings:</b> inpatient and outpatient<br/><b>Intervention:</b> antidepressants<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Antidepressants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a continuous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy as a continuous outcome (SMD) in the intervention groups was<br/><b>0.52 standard deviations lower</b><br/>(0.92 lower to 0.12 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511 <br/>(7 studies, 8 comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a dichotomous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>427 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b><br/>(243 to 410) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/>(0.57 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>662 <br/>(7 studies, 8 comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts due to any cause (acceptability)</b><br/>Follow‐up: 4–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b><br/>(105 to 328) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/>(0.52 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>479<br/>(9 studies, 10 comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level as the general quality of the studies included in the review was poor, with 50% of the studies at high risk of bias in the ROB 2 assessment. Most studies had a very high dropout rate (bias due to missing outcome) and very few studies described the randomisation process in detail.<br/><sup>b</sup> Downgraded two levels due to serious heterogeneity (I² = 74%). An I² statistic between 50% and 75% suggests a serious risk of inconsistency (unexplained heterogeneity), which may arise from relevant differences in populations, interventions and outcomes of the studies entered into the analysis.<br/><sup>c</sup> Downgraded two levels due to serious heterogeneity (I² = 58%). See note <sup>b</sup>.<br/><sup>d</sup> Downgraded one level due to low number of participants recruited and 95% CIs included both no effect and appreciable benefit or appreciable harm, which suggests the risk of very serious imprecision of the results and thus low confidence in their reliability.<br/><sup>e</sup> Downgraded one level due to moderate heterogeneity (I² = 45%). An I<sup>2</sup> statistic between 30% and 60% suggests a moderate risk of inconsistency (unexplained heterogeneity), which may arise from relevant differences in populations, interventions and outcomes of the studies entered into the analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antidepressants compared to placebo for people with cancer and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011006-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Selective serotonin reuptake inhibitors (SSRIs) compared to tricyclic antidepressants (TCAs) for people with cancer and depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>SSRIs compared to TCAs for people with cancer and depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with cancer and depression<br/><b>Settings:</b> inpatient and outpatient<br/><b>Intervention:</b> SSRIs<br/><b>Comparison:</b> TCAs </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TCAs</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SSRIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a continuous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy as a continuous outcome (SMD) in the intervention groups was<br/><b>0.08 standard deviations lower</b><br/>(0.34 lower to 0.18 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Efficacy as a dichotomous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b> (0.78 to 1.53 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>199<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>388 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b><br/>(256 to 799) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dropouts due to any cause (acceptability)</b><br/>Follow‐up: 4–12 weeks </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> <br/>(0.53 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>237<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>261 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b><br/>(138 to 339) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>SSRI:</b> selective serotonin reuptake inhibitor; <b>TCA:</b> tricyclic antidepressant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level as no studies described the outcome assessment as blinded. This should be considered a major limitation, which is likely to result in a biased assessment of the intervention effect.<br/><sup>b</sup> Downgraded two levels as very low number of participants recruited (fewer than 100 individuals in both treatment arms) and 95% CIs included both no effect and appreciable benefit or appreciable harm, which suggests the risk of very serious imprecision of the results and thus low confidence in their reliability.<br/><sup>c</sup> Downgraded one level as one study out of three had a high risk of sponsorship bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Selective serotonin reuptake inhibitors (SSRIs) compared to tricyclic antidepressants (TCAs) for people with cancer and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011006-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mirtazapine compared to tricyclic antidepressants (TCA) for people with cancer and depression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mirtazapine compared to placebo for people with cancer and depression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cancer and depression<br/><b>Settings:</b> inpatient and outpatient<br/><b>Intervention:</b> mirtazapine<br/><b>Comparison:</b> TCA </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mirtazapine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TCA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a continuous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy as a continuous outcome (MD) in the intervention groups was <b>4.80 lower</b> in the intervention group (9.70 lower to 0.10 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy as a dichotomous outcome</b><br/>Follow‐up: 6–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(46 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.81</b> (0.60 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts due to any cause (acceptability)</b><br/>Follow‐up: 4–12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><br/>(62 to 662) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.20 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TCA:</b> tricyclic antidepressant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels as overall risk of bias was high according to the RoB 2 assessment, due to missing outcome data.<br/><sup>b</sup> Downgraded two levels as very low number of participants recruited (fewer than 100 individuals in both treatment arms) and 95% CIs included both no effect and appreciable benefit or appreciable harm, which suggests the risk of very serious imprecision of the results and thus low confidence in their reliability.<br/><sup>c</sup> Downgraded one level as overall risk of bias was moderate according to the RoB 2 assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Mirtazapine compared to tricyclic antidepressants (TCA) for people with cancer and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/full#CD011006-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Depression: efficacy as a continuous outcome at 6–12 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.92, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.79, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.95, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐2.44, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 SSRIs vs TCAs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.34, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Paroxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.73, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Paroxetine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.46, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Fluoxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.45, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mirtazapine vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.80 [‐9.70, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Depression: efficacy as a continuous outcome at 6–12 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Depression: efficacy as a continuous outcome at 1–4 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.87, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.62, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐1.26, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Mirtazapine vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.00 [‐10.63, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Depression: efficacy as a continuous outcome at 1–4 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Depression: efficacy as a dichotomous outcome at 6–12 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.57, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.42, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.42, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 SSRI vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.78, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Paroxetine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.79, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Paroxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.33, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Mirtazapine vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Depression: efficacy as a dichotomous outcome at 6–12 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Social adjustment at 6–12 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Antidepressants vs antidepressants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.38, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Paroxetine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.38, 0.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Social adjustment at 6–12 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Quality of life at 6–12 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.27, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.27, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Antidepressants vs antidepressants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.50 [0.21, 12.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Paroxetine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.50 [0.21, 12.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Quality of life at 6–12 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Dropouts due to any cause (acceptability)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.52, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.84, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.24, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.25, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 SSRI vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.53, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Fluoxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.29, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Paroxetine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Paroxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.37, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Mirtazapine vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.20, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Dropouts due to any cause (acceptability)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Dropouts due to inefficacy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.10, 7.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.16, 52.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Antidepressants vs antidepressants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.14, 5.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Fluoxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Paroxetine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 Paroxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.14, 5.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Dropouts due to inefficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Dropouts due to adverse effects (tolerability)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.54, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.71, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Tricyclic antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.04, 7.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Antidepressants vs antidepressants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.55, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Fluoxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.41, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Paroxetine vs amitriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.38, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.3 Paroxetine vs desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.18, 16.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Dropouts due to adverse effects (tolerability)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: psychiatric diagnosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.98, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Participants with major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.38, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Participants with adjustment disorder, dysthymic disorder, depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.67, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 SSRI vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.41, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Participants with major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.41, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Mirtazapine vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.80 [‐9.70, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: psychiatric diagnosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: cancer site</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.92, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Participants with breast cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.38, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Participants with other cancer types</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.90, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Antidepressants vs antidepressants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.41, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Participants with breast cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.41, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Participants with other cancer types</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐1.15, 0.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: cancer site</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: cancer stage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.66, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Participants with an early‐stage cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.65, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 Participants with late‐stage cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐1.30, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Antidepressants vs antidepressants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [‐1.61, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Participants with early‐stage cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [‐1.61, 2.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: cancer stage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis: excluding trials that did not employ depressive symptoms as their primary outcome</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.98, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.58, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.95, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.3 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐2.44, 0.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis: excluding trials that did not employ depressive symptoms as their primary outcome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011006-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sensitivity analysis: excluding trials with imputed data</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Antidepressants vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.10, ‐0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.90, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 Other antidepressants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐2.44, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Mirtazapine vs TCA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.80 [‐8.85, ‐0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sensitivity analysis: excluding trials with imputed data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#CD011006-tbl-0016">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Antidepressants vs placebo</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.1 SSRIs</b> </p> </td> </tr> <tr class="study-data"> <td> <p>EUCTR2008‐002159‐25‐FR</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as randomized, however no detail is provided concerning the generation of the allocation sequence nor whether it was concealed or not until participants were enrolled (unpublished study). No major imbalances between intervention groups according to the results posted on clinicaltrials.gov </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. No further detail is provided concerning the blinding procedure (unpublished study). A mITT approach has been used to measure the outcome, excluding from the analysis those patients who were unable to follow up. Completers were analyzed as randomized </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>8/20 patients in the escitalopram group (40%) and 6/18 in the placebo group (33%) were unable to follow up, hence their outcome wasn't available. No evidence is provided to justify the fact that the result was not biased by missing outcome data. Missingness in the outcome could depend on its true value, however specific reasons are provided for those drop‐outs that occurred and seem balanced between the two intervention groups, making it unlikely that this missingness of the outcome might depend on its true value </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The Montgomery‐Asberg Depression Rating Scale (MADRS) is a validated tool to measure the outcome in question. No information is available concerning the frequency and way the outcome was measured in the two intervention groups. Concomitant medications for insomnia and nausea were allowed in both groups according to the study protocol. No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>On the study protocol HADS scale was listed as the main tool to evaluate efficacy. However only results of the assessment with the MADRS and CES‐D scales are available. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The overall risk of bias is high. The study is unpublished. Important information on the way the outcome was measured are indeed missing (no detail on randomization/ concealment of the allocation sequence, no clear detail on how the outcome was measured in the two study groups). Moreover the attrition rates are high in both group and the way the main outcome was measured was not coherent with the study protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>Fisch 2003</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "[...] randomly assigned in a double‐blind manner to receive either fluoxetine (20‐mg tablets) or an identical placebo tablet. The randomisation was performed centrally through a preprinted randomisation table, and the study drug was sent by overnight mail directly to the patient". It is safe to assume that this method of randomization might have ensured concealment of the allocation sequence. No major imbalances between intervention groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. Fluoxetine and placebo pills were identical in appearance. No further detail is provided concerning the blinding procedure. A mITT approach has been used to measure the outcome, excluding from the analysis those patients who were unable to follow up. The other patients were analyzed as randomized </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>26/64 patients in the fluoxetine group (40%) and 21/65 in the placebo group (32,3%) were unable to follow up, hence their outcome wasn't available. No evidence is provided to justify the fact that the result was not biased by missing outcome data. Missingness in the outcome could depend on its true value, drop out to adverse events are reported in the paper constitute only a small percentage of the total drop‐out rates and are well distributed among the two intervention groups. However other reasons for drop‐outs are not described in enough detail to estimate how likely it is that the missingness in the outcome might have depended on its true value </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The BZSDS (Brief Zung Self‐Rating Depression Scale) is a validated tool to measure the outcome in question. According to study authors "The mean interval between visits (in weeks) was similar for patients in each treatment arm" and "Longitudinal assessments were performed at baseline and every 3 to 6 weeks thereafter and included the measurement of QOL and depression. The visit interval varied among patients and often depended on the schedule for anticancer therapy. Patients were assessed for 12 weeks, and complete assessment involved three to five sessions of data collection (depending on the individual patient’s visit intervals)." No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or pre‐specified analysis plan is available for the study in question. However relevant data for the pre‐specified (methods) outcomes are well‐reported (results). The way the outcome was measured seems coherent with the prespecified plan (methods). It is however possible that the study authors measured other outcomes and/or conducted multiple analyses, but did not report them. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We considered the measurement of the outcome to be at high risk of bias for the high attrition rates of study participants in both groups (40% in the fluoxetine group, 32,3% in the fluoxetine group). Furthermore reasons for drop‐outs are not described in enough detail. </p> </td> </tr> <tr class="study-data"> <td> <p>Musselman 2006</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as randomized, however no detail is provided concerning the randomization of the allocation sequence nor whether it was concealed or not until participants were enrolled. No major imbalances between intervention groups (with the exception of stage, being less advanced in the placebo‐treated group, and previous chemotherapy, being less frequent in the placebo‐treated group) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. No further detail is provided concerning the blinding procedure. Patients were analyzed as randomized. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>5 out of 13 patients in the paroxetine group (40%), 4 out of 11 patients in the desipramine group (36%) and 5 out of 11 patients in the placebo group (45%) were unable to follow up, hence their outcome wasn't available. No evidence is provided to justify the fact that the result was not biased by missing outcome data. Reason for leaving the study are well described and overall balanced between groups, however dropout rates are relevant. Moreover, a relevant portion of missing data are possibly related to the true outcome (2 patients in the paroxetine group versus 2 in the desipramine group versus 0 patients in the placebo group dropped due to inefficacy) </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>the Hamilton Depression Rating Scale (HAM‐D) is a validated tool to measure the outcome in question. Patients in both groups were assessed for both efficacy and adverse events at baseline, weekly during weeks 1 through 6 and on a monthly basis thereafter for a total of 5 months of double‐blind, randomized treatment. No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or pre‐specified analysos plan is available for the study in question. However prespecified outcomes are reported for the endpoint assessment (week 6) in the methods section. The way the outcome was measured seems coherent with the prespecified plan (methods). It is however possible that the study authors measured other outcomes and/or conducted multiple analyses, but did not report them. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although the overall quality of the study was acceptable, we considered the way the outcome was measured to be at high risk of bias for the high attrition rates. Moreover the reasons for the dropouts among the three groups are not well balanced enough and they may be related to the true outcome </p> </td> </tr> <tr class="study-data"> <td> <p>Razavi 1996</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as randomized, however no detail is provided concerning the randomization of the allocation sequence nor whether it was concealed or not until participants were enrolled. No major imbalances between intervention groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. No further detail is provided concerning the blinding procedure. A mITT approach has been used to measure the outcome, excluding from the analysis those patients who were unable to follow up. The other patients were analyzed as randomized </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>15/45 patients in the tluoxetine group (33%) and 7/46 patients in the placebo group (15,2%) were unable to follow up, hence their outcome wasn't available. No evidence is provided to justify the fact that the result was not biased by missing outcome data. Missingness in the outcome it's likely to depend on its true value. Indeed, there is imbalance between the two groups, even though reasons for dropping out from the study are well described. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The Hospital Anxiety and Depression scale is a validated tool to measure the outcome in question. The outcome was measured at regular follow up visits in both intervention groups. No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or pre‐specified analysis plan is available for the study in question. Outcomes are not clearly pre‐specified in the method section (quote: "[...] evaluate, in a double‐blind placebo‐controlled design, the effectiveness of fluoxetine to treat and/or to control anxiety and depression [...]"). For relevant outcomes mean scores on rating scales are reported for 'visit 1' (but it is not clearly explained if it matches with the baseline point) and for 'visit 5'. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the measurement of this outcome to be at high risk of bias. The randomization process is not described in enough detail and the attrition rates are quite high and not well balanced between the two groups (although the reasons for the drop‐outs are described ). The way the outcomes were measured and analyzed were not pre‐specified in enough detail in the method section </p> </td> </tr> <tr class="study-data"> <td> <p>Tavakoli Ardakani 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as randomized. Generation of the allocation sequence was random and it was concealed until participants were enrolled and assigned to interventions. Quote: "Both placebo and sertraline tablets were prepared and packaged by the same manufacturer (SobhanTM Pharmaceutical Company, Rasht, Iran), were visually identical and labelled with a code number from the random list. At inclusion, general practitioners gave the code number from the drug unit to the patient and all patient related data." No major imbalances between intervention groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. No further detail is provided concerning the blinding procedure; A mITT approach has been used to measure the outcome, excluding from the analysis those patients who were unable to follow up. The other patients were analyzed as randomized </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>9 patients out of 56 (16%) were lost to follow‐up and their outcome wasn't available. Of the 9 patients who were lost to follow up 5 belonged to the sertraline group and 4 to the placebo group. The number of patients with missing outcome data is inferior to 20% and this can be considered acceptable considered the type of population and the trial intervention </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The Hospital Anxiety and Depression scale is a validated tool to measure the outcome in question; The outcome was measured at 3 and 6 weeks in both intervention groups; No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or pre‐specified analysis plan is available for the study in question. Relevant data for the pre‐specified (methods) outcomes are well‐reported (results). It is however possible that the study authors measured other outcomes and/or conducted multiple analyses, but did not report them. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The overall assessment of the outcome had some concerns for a risk of bias, mainly due to the lack of a registered protocol or a pre specified analysis plan </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.2 TCAs</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Musselman 2006</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as randomized, however no detail is provided concerning the randomization of the allocation sequence nor whether it was concealed or not until participants were enrolled. No major imbalances between intervention groups (with the exception of stage, being less advanced in the placebo‐treated group, and previous chemotherapy, being less frequent in the placebo‐treated group) </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. No further detail is provided concerning the blinding procedure. Patients were analyzed as randomized. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>5 out of 13 patients in the paroxetine group (40%), 4 out of 11 patients in the desipramine group (36%) and 5 out of 11 patients in the placebo group (45%) were unable to follow up, hence their outcome wasn't available. No evidence is provided to justify the fact that the result was not biased by missing outcome data. Reason for leaving the study are well described and overall balanced between groups, however dropout rates are relevant. Moreover, a relevant portion of missing data are possibly related to the true outcome (2 patients in the paroxetine group versus 2 in the desipramine group versus 0 patients in the placebo group dropped due to inefficacy) </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>the Hamilton Depression Rating Scale (HAM‐D) is a validated tool to measure the outcome in question. Patients in both groups were assessed for both efficacy and adverse events at baseline, weekly during weeks 1 through 6 and on a monthly basis thereafter for a total of 5 months of double‐blind, randomized treatment. No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or pre‐specified analysos plan is available for the study in question. However prespecified outcomes are reported for the endpoint assessment (week 6) in the methods section. The way the outcome was measured seems coherent with the prespecified plan (methods). It is however possible that the study authors measured other outcomes and/or conducted multiple analyses, but did not report them. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although the overall quality of the study was acceptable, we considered the way the outcome was measured to be at high risk of bias for the high attrition rates. Moreover the reasons for the dropouts among the three groups are not well balanced enough and they may be related to the true outcome </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.3 Other antidepressants</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Liu 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "patients were randomized into different groups through a computer‐generated randomized list using the SPSS software (SPSS Inc., Chicago, USA)". No detail is provided concerning the concealment of the allocation sequence". No major imbalances between intervention groups. No further detail is provided concerning the concealment of the allocation sequence, however, although information on the sequence generation and the allocation concealment are poorly reported, we considered that, given the overall good methodological quality of the study, major issues of the randomization process are unlikely to have occurred. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. No further detail is provided concerning the blinding procedure. Patients were analyzed as randomized </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>According to study authors "No patients were lost to follow up"</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The Hospital Anxiety and Depression scale is a validated tool to measure the outcome in question. The outcome was measured at day 1,3,7, at 1 month and 3 months in both intervention groups. No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or pre‐specified analysis plan is available for the study in question. However relevant data for the pre‐specified (methods) outcomes are well‐reported (results). The way the outcome was measured seems coherent with the prespecified plan (methods). It is however possible that the study authors measured other outcomes and/or conducted multiple analyses, but did not report them. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We considered the measurement of the outcome to have some concerns of risk of bias. The overall methodology was good, all patients were randomized as analyzed and no drop‐out occurred. The way the outcome was measured is appropriate, however no protocol or pre‐specified analysis plan was available for the study in question </p> </td> </tr> <tr class="study-data"> <td> <p>Van Heeringen 1996</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as randomized, however no detail is provided concerning the randomization of the allocation sequence nor whether it was concealed or not until participants were enrolled. No major imbalances between intervention groups </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study described as double blind. Placebo and mianserin pills were identical in appearance. No further detail is provided concerning the blinding procedure. A mITT analysis has been conducted, including in the final analysis all patients who had at least 1 post‐baseline follow‐up assessment. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>6/28 patients in the tluoxetine group (33%) and 15/27 patients in the placebo group (55%) were unable to follow up, hence their outcome wasn't available. No evidence is provided to justify the fact that the result was not biased by missing outcome data. Quote: "Significantly more placebo‐treated patients (n = 15) than mianserin‐treated patients (n = 6) prematurely terminated the study (Fishers' exact test P,=0.014). When withdrawals because of lack of efficacy were analysed, the difference was again significant and in favour of mianserin (2 and 11 patients in the mianserin and placebo treatment group, respec tively; Fisher's exact test, P= 0.006)." Missing of the outcome can indeed be explained by lack of efficacy in the placebo group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The Hospital Anxiety and Depression scale is a validated tool to measure the outcome in question. The outcome was measured at regular follow up visits in both intervention groups at week 2, 4 and 6. No other reason to suspect that this kind of bias might have occurred. No detail is provided concerning the blinding of the assessors, however it seems implied in the double‐blind design of the study </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or pre‐specified analysos plan is available for the study in question. Outcomes are not clearly prespecified (quote: "The aim of our study was to evaluate the efficacy and safety of mianserin in patients with breast cancer [...]"). However, mean change scores on HDRS, response rates and rates of relevant adverse events are reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We considered the measurement of the outcome to be at high risk of bias. The attrition rates are high in both groups, with a significant imbalance between the two arms for the droupouts due to lack of efficacy (2 in the mianserin group vs 11 in the placebo group). The potential bias due to missing of outcome data favors placebo over comparator </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Antidepressants vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011006.pub4/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011006.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011006-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011006-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011006-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011006-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011006-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD011006-note-0017">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD011006-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD011006-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011006-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD011006-note-0011">Português</a> </li> <li class="section-language"> <a class="" href="th#CD011006-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011006-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011006\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011006\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011006\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011006\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011006\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Nio3SV1W&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011006.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011006.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011006.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011006.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011006.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729211230"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011006.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729211234"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011006.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed7590fe8f55b',t:'MTc0MDcyOTIxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 